|
|
| (2 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | [[TempP(4)]] | | [[TempP(4)]] |
| − |
| |
| − |
| |
| − |
| |
| − | {{tp|p=33097846|t=2020. The race to make COVID antibody therapies cheaper and more potent.|pdf=|usr=020}}
| |
| − | {{tp|p=33069206|t=2020. Antiviral essential oils incorporated in nanocarriers: strategy for prevention from COVID-19 and future infectious pandemics.|pdf=|usr=020}}
| |
| − | {{tp|p=33139569|t=2020. Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection.|pdf=|usr=020}}
| |
| − |
| |
| − | {{tp|p=33064991|t=2020. Timeline: Vaccines.|pdf=|usr=020}}
| |
| − | {{tp|p=33160446|t=2020. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33137690|t=2020. Interaction of small molecules with the SARS-CoV-2 main protease in silico and in vitro validation of potential lead compounds using an enzyme-linked immunosorbent assay.|pdf=|usr=020}}
| |
| − | {{tp|p=33126128|t=2020. In silico identification of Tretinoin as a SARS-CoV-2 envelope (E) protein ion channel inhibitor.|pdf=|usr=020}}
| |
| − | {{tp|p=33131530|t=2020. Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33074111|t=2020. Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs.|pdf=|usr=020}}
| |
| − | {{tp|p=33065388|t=2020. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.|pdf=|usr=020}}
| |
| − | {{tp|p=33046113|t=2020. Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: a pilot study.|pdf=|usr=020}}
| |
| − | {{tp|p=33172477|t=2020. Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33159417|t=2020. Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33179852|t=2020. Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33130275|t=2020. COVID-19 and antimalarials. Have we been doing it wrong all along?|pdf=|usr=020}}
| |
| − | {{tp|p=33130280|t=2020. Unravelling high-affinity binding compounds towards transmembrane protease serine 2 enzyme in treating SARS-CoV-2 infection using molecular modelling and docking studies.|pdf=|usr=020}}
| |
| − | {{tp|p=33130279|t=2020. In silico identification of strong binders of the SARS-CoV-2 receptor-binding domain.|pdf=|usr=020}}
| |
| − | {{tp|p=33190802|t=2020. Recent progress of antiviral therapy for coronavirus disease 2019.|pdf=|usr=020}}
| |
| − | {{tp|p=33131721|t=2020. Screening Malaria-box compounds to identify potential inhibitors against SARS-CoV-2 M(pro), using molecular docking and dynamics simulation studies.|pdf=|usr=020}}
| |
| − | {{tp|p=33098835|t=2020. Translating bioactive peptides for COVID-19 therapy.|pdf=|usr=020}}
| |
| − | {{tp|p=33069672|t=2020. ADMET profile and virtual screening of plant and microbial natural metabolites as SARS-CoV-2 S1 glycoprotein receptor binding domain and main protease inhibitors.|pdf=|usr=020}}
| |
| − | {{tp|p=33068588|t=2020. Perspectives on mechanistic implications of ROS inducers for targeting viral infections.|pdf=|usr=020}}
| |
| − | {{tp|p=33065096|t=2020. Computational and theoretical exploration for clinical suitability of Remdesivir drug to SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33065092|t=2020. Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33160938|t=2020. Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33193454|t=2020. CoVaccine HT Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization.|pdf=|usr=020}}
| |
| − | {{tp|p=33193448|t=2020. Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response.|pdf=|usr=020}}
| |
| − | {{tp|p=33193427|t=2020. Tea Bioactive Modulate Innate Immunity: In Perception to COVID-19 Pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33193385|t=2020. Perspective: Reducing SARS-CoV2 Infectivity and Its Associated Immunopathology.|pdf=|usr=020}}
| |
| − | {{tp|p=33163000|t=2020. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33133090|t=2020. Targeting Lipid Rafts-A Potential Therapy for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33133071|t=2020. Potential Challenges for Coronavirus (SARS-CoV-2) Vaccines Under Trial.|pdf=|usr=020}}
| |
| − | {{tp|p=33123165|t=2020. Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines.|pdf=|usr=020}}
| |
| − | {{tp|p=33117404|t=2020. As Plain as the Nose on Your Face: The Case for A Nasal (Mucosal) Route of Vaccine Administration for Covid-19 Disease Prevention.|pdf=|usr=020}}
| |
| − | {{tp|p=33117391|t=2020. An Effective COVID-19 Vaccine Needs to Engage T Cells.|pdf=|usr=020}}
| |
| − | {{tp|p=33117359|t=2020. Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33101309|t=2020. Emerging Concepts and Technologies in Vaccine Development.|pdf=|usr=020}}
| |
| − | {{tp|p=33101291|t=2020. Perspective: The Potential Effects of Naringenin in COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33072130|t=2020. Cell-Free Therapies: Novel Approaches for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33072111|t=2020. Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment.|pdf=|usr=020}}
| |
| − | {{tp|p=33072093|t=2020. Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors-The Current Status.|pdf=|usr=020}}
| |
| − | {{tp|p=33042151|t=2020. Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective.|pdf=|usr=020}}
| |
| − | {{tp|p=33093657|t=2020. Self-amplifying RNA vaccines for infectious diseases.|pdf=|usr=020}}
| |
| − | {{tp|p=33184504|t=2020. Molecular targeting of vulnerable RNA sequences in SARS CoV-2: identifying clinical feasibility.|pdf=|usr=020}}
| |
| − | {{tp|p=33189776|t=2020. Repurposed drugs and nutraceuticals targeting envelope protein: A possible therapeutic strategy against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33161002|t=2020. Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab.|pdf=|usr=020}}
| |
| − | {{tp|p=33161557|t=2020. Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview.|pdf=|usr=020}}
| |
| − | {{tp|p=33062618|t=2020. Immunoglobulin G2 Antibody as a Potential Target for COVID-19 Vaccine.|pdf=|usr=020}}
| |
| − | {{tp|p=33184600|t=2020. Peptide modelling and screening against human ACE2 and spike glycoprotein RBD of SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33083517|t=2020. Leaving no stone unturned: Allosteric targeting of SARS-CoV-2 spike protein at putative druggable sites disrupts human angiotensin-converting enzyme interactions at the receptor binding domain.|pdf=|usr=020}}
| |
| − | {{tp|p=33028776|t=2020. Implications for White Matter Vulnerability to Anti-interleukin-6 Receptor Antibody Treatment.|pdf=|usr=020}}
| |
| − | {{tp|p=32999229|t=2020. Tocilizumab-induced Leukoencephalopathy with a Reversible Clinical Course.|pdf=|usr=020}}
| |
| − | {{tp|p=32963155|t=2020. Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33191372|t=2020. A Favipiravir-induced Fever in a Patient with COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=32980157|t=2020. Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33068560|t=2020. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon.|pdf=|usr=020}}
| |
| − | {{tp|p=33094705|t=2020. Caffeine and caffeine-containing pharmaceuticals as promising inhibitors for 3-chymotrypsin-like protease of SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33094701|t=2020. Potential therapeutic use of corticosteroids as SARS CoV-2 main protease inhibitors: a computational study.|pdf=|usr=020}}
| |
| − | {{tp|p=33094680|t=2020. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.|pdf=|usr=020}}
| |
| − | {{tp|p=33089730|t=2020. Screening of phytochemicals as potent inhibitor of 3-chymotrypsin and papain-like proteases of SARS-CoV2: an in silico approach to combat COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33089728|t=2020. Prevention of SARS-CoV-2 cell entry: insight from in silico interaction of drug-like alkaloids with spike glycoprotein, human ACE2, and TMPRSS2.|pdf=|usr=020}}
| |
| − | {{tp|p=33084512|t=2020. Targeting the 3CLpro and RdRp of SARS-CoV-2 with phytochemicals from medicinal plants of the Andean Region: molecular docking and molecular dynamics simulations.|pdf=|usr=020}}
| |
| − | {{tp|p=33073716|t=2020. A computational and bioinformatic analysis of ACE2: an elucidation of its dual role in COVID-19 pathology and finding its associated partners as potential therapeutic targets.|pdf=|usr=020}}
| |
| − | {{tp|p=33073712|t=2020. Structural basis for the inhibition of SARS-CoV2 main protease by Indian medicinal plant-derived antiviral compounds.|pdf=|usr=020}}
| |
| − | {{tp|p=33073699|t=2020. Antiviral activity of traditional medicinal plants from Ayurveda against SARS-CoV-2 infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33155531|t=2020. Identification and characterization of novel RdRp and Nsp15 inhibitors for SARS-COV2 using computational approach.|pdf=|usr=020}}
| |
| − | {{tp|p=33155524|t=2020. Computationally validated SARS-CoV-2 CTL and HTL Multi-Patch vaccines, designed by reverse epitomics approach, show potential to cover large ethnically distributed human population worldwide.|pdf=|usr=020}}
| |
| − | {{tp|p=33150860|t=2020. Traditional medicinal plants against replication, maturation and transmission targets of SARS-CoV-2: computational investigation.|pdf=|usr=020}}
| |
| − | {{tp|p=33150855|t=2020. SARS-CoV-2 M(pro) inhibitors: identification of anti-SARS-CoV-2 M(pro) compounds from FDA approved drugs.|pdf=|usr=020}}
| |
| − | {{tp|p=33146070|t=2020. Pathway enrichment analysis of virus-host interactome and prioritization of novel compounds targeting the spike glycoprotein receptor binding domain-human angiotensin-converting enzyme 2 interface to combat SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33143552|t=2020. Identification of natural inhibitors against Mpro of SARS-CoV-2 by molecular docking, molecular dynamics simulation, and MM/PBSA methods.|pdf=|usr=020}}
| |
| − | {{tp|p=33140706|t=2020. Targeting the initiation and termination codons of SARS-CoV-2 spike protein as possible therapy against COVID-19: the role of novel harpagide 5-O-beta-D-glucopyranoside from Clerodendrum volubile P Beauv. (Labiatae).|pdf=|usr=020}}
| |
| − | {{tp|p=33140703|t=2020. Targeting SARS-CoV-2 nucleocapsid oligomerization: Insights from molecular docking and molecular dynamics simulations.|pdf=|usr=020}}
| |
| − | {{tp|p=33140695|t=2020. Computer aided identification of potential SARS CoV-2 main protease inhibitors from diterpenoids and biflavonoids of Torreya nucifera leaves.|pdf=|usr=020}}
| |
| − | {{tp|p=33138699|t=2020. Emerging of composition variations of SARS-CoV-2 spike protein and human ACE2 contribute to the level of infection: in silico approaches.|pdf=|usr=020}}
| |
| − | {{tp|p=33131430|t=2020. An in-silico analysis of ivermectin interaction with potential SARS-CoV-2 targets and host nuclear importin alpha.|pdf=|usr=020}}
| |
| − | {{tp|p=33141117|t=2020. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome.|pdf=|usr=020}}
| |
| − | {{tp|p=33168277|t=2020. Successful treatment of a critical COVID-19 patient with tocilizumab.|pdf=|usr=020}}
| |
| − | {{tp|p=33072190|t=2020. Systematic analyses on the potential immune and anti-inflammatory mechanisms of Shufeng Jiedu Capsule against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-caused pneumonia.|pdf=|usr=020}}
| |
| − | {{tp|p=33034095|t=2020. Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.|pdf=|usr=020}}
| |
| − | {{tp|p=33080692|t=2020. Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19: A case report.|pdf=|usr=020}}
| |
| − | {{tp|p=33036293|t=2020. Clean Grinding Technique: A Facile Synthesis and In Silico Antiviral Activity of Hydrazones, Pyrazoles, and Pyrazines Bearing Thiazole Moiety against SARS-CoV-2 Main Protease (M(pro)).|pdf=|usr=020}}
| |
| − | {{tp|p=33142770|t=2020. In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33138197|t=2020. Antiviral and Immunomodulatory Effects of Phytochemicals from Honey against COVID-19: Potential Mechanisms of Action and Future Directions.|pdf=|usr=020}}
| |
| − | {{tp|p=33137894|t=2020. Molecular Insights into Human Transmembrane Protease Serine-2 (TMPS2) Inhibitors against SARS-CoV2: Homology Modelling, Molecular Dynamics, and Docking Studies.|pdf=|usr=020}}
| |
| − | {{tp|p=33105830|t=2020. Probiotics in Treatment of Viral Respiratory Infections and Neuroinflammatory Disorders.|pdf=|usr=020}}
| |
| − | {{tp|p=33066278|t=2020. High-Throughput Screening for Inhibitors of the SARS-CoV-2 Protease Using a FRET-Biosensor.|pdf=|usr=020}}
| |
| − | {{tp|p=33053830|t=2020. Docking and QSAR of Aminothioureas at the SARS-CoV-2 S-Protein-Human ACE2 Receptor Interface.|pdf=|usr=020}}
| |
| − | {{tp|p=33050360|t=2020. Protease Inhibitory Effect of Natural Polyphenolic Compounds on SARS-CoV-2: An In Silico Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33172092|t=2020. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M(pro) Protease.|pdf=|usr=020}}
| |
| − | {{tp|p=33147850|t=2020. Application of Humanized Zebrafish Model in the Suppression of SARS-CoV-2 Spike Protein Induced Pathology by Tri-Herbal Medicine Coronil via Cytokine Modulation.|pdf=|usr=020}}
| |
| − | {{tp|p=33147821|t=2020. Epitope-Based Immunoinformatics Approach on Nucleocapsid Protein of Severe Acute Respiratory Syndrome-Coronavirus-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33053279|t=2020. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.|pdf=|usr=020}}
| |
| − | {{tp|p=33031652|t=2020. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33072338|t=2020. Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach.|pdf=|usr=020}}
| |
| − | {{tp|p=33181320|t=2020. Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: A retrospective multicenter cohort study.|pdf=|usr=020}}
| |
| − | {{tp|p=33044019|t=2020. Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality.|pdf=|usr=020}}
| |
| − | {{tp|p=33163253|t=2020. Crystal structure of SARS-CoV-2 main protease in complex with the natural product inhibitor shikonin illuminates a unique binding mode.|pdf=|usr=020}}
| |
| − | {{tp|p=33033405|t=2020. Preemptive interleukin-6 blockade in patients with COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33110184|t=2020. Protection against SARS-CoV-2 by BCG vaccination is not supported by epidemiological analyses.|pdf=|usr=020}}
| |
| − | {{tp|p=33060704|t=2020. Statin use is associated with lower disease severity in COVID-19 infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33051534|t=2020. Lack of tocilizumab effect on mortality in COVID19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33051517|t=2020. Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats.|pdf=|usr=020}}
| |
| − | {{tp|p=33046764|t=2020. Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation.|pdf=|usr=020}}
| |
| − | {{tp|p=33154498|t=2020. Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports.|pdf=|usr=020}}
| |
| − | {{tp|p=33154452|t=2020. Impact of tocilizumab administration on mortality in severe COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33154404|t=2020. Searching for target-specific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach.|pdf=|usr=020}}
| |
| − | {{tp|p=33051445|t=2020. A systematic review of SARS-CoV-2 vaccine candidates.|pdf=|usr=020}}
| |
| − | {{tp|p=33040075|t=2020. Azvudine (FNC): a promising clinical candidate for COVID-19 treatment.|pdf=|usr=020}}
| |
| − | {{tp|p=33144565|t=2020. Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33144557|t=2020. Outsmarting SARS-CoV-2 by empowering a decoy ACE2.|pdf=|usr=020}}
| |
| − | {{tp|p=33188163|t=2020. Baicalein inhibits SARS-CoV-2/VSV replication with interfering mitochondrial oxidative phosphorylation in a mPTP dependent manner.|pdf=|usr=020}}
| |
| − | {{tp|p=33097846|t=2020. The race to make COVID antibody therapies cheaper and more potent.|pdf=|usr=020}}
| |
| − | {{tp|p=33069206|t=2020. Antiviral essential oils incorporated in nanocarriers: strategy for prevention from COVID-19 and future infectious pandemics.|pdf=|usr=020}}
| |
| − | {{tp|p=33139569|t=2020. Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection.|pdf=|usr=020}}
| |
| − |
| |
| − | {{tp|p=33078827|t=2020. MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs.|pdf=|usr=020}}
| |
| − | {{tp|p=33147623|t=2020. A review on drug repurposing applicable to COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33147627|t=2020. Computational strategies to combat COVID-19: useful tools to accelerate SARS-CoV-2 and coronavirus research.|pdf=|usr=020}}
| |
| − | {{tp|p=33061304|t=2020. Challenges for Mesenchymal Stem Cell-Based Therapy for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33116043|t=2020. Stabilizing mast cells by commonly used drugs: a novel therapeutic target to relieve post-COVID syndrome?|pdf=|usr=020}}
| |
| − | {{tp|p=33116037|t=2020. Is amiloride a promising cardiovascular medication to persist in the COVID-19 crisis?|pdf=|usr=020}}
| |
| − | {{tp|p=33127568|t=2020. Union is strength: antiviral and anti-inflammatory drugs for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33124007|t=2020. Remdesivir: Critical Clinical Appraisal for COVID 19 Treatment.|pdf=|usr=020}}
| |
| − | {{tp|p=33176367|t=2020. Favipiravir and COVID-19: A Simplified Summary.|pdf=|usr=020}}
| |
| − | {{tp|p=33161277|t=2020. COVID-19 update: The race to therapeutic development.|pdf=|usr=020}}
| |
| − | {{tp|p=33132205|t=2020. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.|pdf=|usr=020}}
| |
| − | {{tp|p=33095409|t=2020. Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease.|pdf=|usr=020}}
| |
| − | {{tp|p=33078372|t=2020. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33068263|t=2020. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.|pdf=|usr=020}}
| |
| − | {{tp|p=33084001|t=2020. The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets.|pdf=|usr=020}}
| |
| − | {{tp|p=33139967|t=2020. Remdesivir in COVID-19 management: availability and relevance to low- and middle-income countries.|pdf=|usr=020}}
| |
| − | {{tp|p=33152333|t=2020. Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead.|pdf=|usr=020}}
| |
| − | {{tp|p=33137330|t=2020. Functional and druggability analysis of the SARS-CoV-2 proteome.|pdf=|usr=020}}
| |
| − | {{tp|p=33117994|t=2020. What Stone-formers Should Know About Vitamin C and D Supplementation in the COVID-19 Era.|pdf=|usr=020}}
| |
| − | {{tp|p=33069187|t=2020. Transfer Factor as an Option for Managing the COVID-19 Pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33092925|t=2020. Identification of tuna protein-derived peptides as potent SARS-CoV-2 inhibitors via molecular docking and molecular dynamic simulation.|pdf=|usr=020}}
| |
| − | {{tp|p=33041708|t=2020. The Functional Medicine Approach to COVID-19: Nutrition and Lifestyle Practices for Strengthening Host Defense.|pdf=|usr=020}}
| |
| − | {{tp|p=33041706|t=2020. The Functional Medicine Approach to COVID-19: Virus-Specific Nutraceutical and Botanical Agents.|pdf=|usr=020}}
| |
| − | {{tp|p=33099620|t=2020. Treating COVID-19: are we missing out the window of opportunity?|pdf=|usr=020}}
| |
| − | {{tp|p=33152616|t=2021. Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus.|pdf=|usr=020}}
| |
| − | {{tp|p=33069124|t=2021. MEDT study of the 1,3-DC reaction of diazomethane with Psilostachyin and investigation about the interactions of some pyrazoline derivatives with protease (M(pro)) of nCoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33173250|t=2020. Towards a novel peptide vaccine for Middle East respiratory syndrome coronavirus and its possible use against pandemic COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33041407|t=2020. Promising terpenes as SARS-CoV-2 spike receptor-binding domain (RBD) attachment inhibitors to the human ACE2 receptor: Integrated computational approach.|pdf=|usr=020}}
| |
| − | {{tp|p=33184722|t=2020. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA.|pdf=|usr=020}}
| |
| − | {{tp|p=33041371|t=2020. Screening of potential drug from Azadiractha Indica (Neem) extracts for SARS-CoV-2: An insight from molecular docking and MD-simulation studies.|pdf=|usr=020}}
| |
| − | {{tp|p=33100380|t=2020. Identification of alkaloids from Justicia adhatoda as potent SARS CoV-2 main protease inhibitors: An in silico perspective.|pdf=|usr=020}}
| |
| − | {{tp|p=33100379|t=2020. DFT Investigation of Atazanavir as Potential Inhibitor for 2019-nCoV Coronavirus M protease.|pdf=|usr=020}}
| |
| − | {{tp|p=33100378|t=2020. Synthesis, anti-bacterial evaluation, DFT study and molecular docking as a potential 3-chymotrypsin-like protease (3CLpro) of SARS-CoV-2 inhibitors of a novel Schiff bases.|pdf=|usr=020}}
| |
| − | {{tp|p=33162722|t=2020. A comprehensive overview of proteomics approach for COVID 19: new perspectives in target therapy strategies.|pdf=|usr=020}}
| |
| − | {{tp|p=33119313|t=2020. Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches.|pdf=|usr=020}}
| |
| − | {{tp|p=33095583|t=2020. Utility of Proteomics in Emerging and Re-Emerging Infectious Diseases Caused by RNA Viruses.|pdf=|usr=020}}
| |
| − | {{tp|p=33090793|t=2020. Targeting Proteases for Treating COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33169644|t=2020. Countermeasure and therapeutic: A(1-7) to treat acute respiratory distress syndrome due to COVID-19 infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33090972|t=2020. Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models.|pdf=|usr=020}}
| |
| − | {{tp|p=32971043|t=2020. Safety and efficacy of the Russian COVID-19 vaccine: more information needed - Authors' reply.|pdf=|usr=020}}
| |
| − | {{tp|p=33032171|t=2020. Hypothesis: Oxytocin is a direct COVID-19 antiviral.|pdf=|usr=020}}
| |
| − | {{tp|p=33069843|t=2020. Antivirals in the time of COVID-19 - not as easy as it looks!|pdf=|usr=020}}
| |
| − | {{tp|p=33052325|t=2020. Spike protein-based epitopes predicted against SARS-CoV-2 through literature mining.|pdf=|usr=020}}
| |
| − | {{tp|p=33049737|t=2020. Pentoxifylline, a drug with antiviral, anti-inflammatory and bronchodilatory effects may be a possible drug candidate for SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33142828|t=2020. Evidence Regarding Vitamin D and Risk of COVID-19 and Its Severity.|pdf=|usr=020}}
| |
| − | {{tp|p=33121019|t=2020. The Emerging Role of Vitamin C in the Prevention and Treatment of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33105731|t=2020. A Review of Nutrition Support Guidelines for Individuals with or Recovering from COVID-19 in the Community.|pdf=|usr=020}}
| |
| − | {{tp|p=33092041|t=2020. The Role of Micronutrients in Support of the Immune Response against Viral Infections.|pdf=|usr=020}}
| |
| − | {{tp|p=33147894|t=2020. Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33049573|t=2020. Pharmaconutrition revisited for critically ill patients with coronavirus disease 2019 (COVID-19): Does selenium have a place?|pdf=|usr=020}}
| |
| − | {{tp|p=33062414|t=2020. Computational perspectives revealed prospective vaccine candidates from five structural proteins of novel SARS corona virus 2019 (SARS-CoV-2).|pdf=|usr=020}}
| |
| − | {{tp|p=33033705|t=2020. Prerequisite of doing clinical trial with drugs in COVID-19 patients: Situational experience.|pdf=|usr=020}}
| |
| − | {{tp|p=33033700|t=2020. Challenges and opportunities for sponsors in conducting clinical trials during a pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33033699|t=2020. Addressing challenges due to the COVID-19 pandemic - A site and investigator perspective.|pdf=|usr=020}}
| |
| − | {{tp|p=33033698|t=2020. COVID-19 effect on clinical research: Single-site risk management experience.|pdf=|usr=020}}
| |
| − | {{tp|p=33031856|t=2020. Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?|pdf=|usr=020}}
| |
| − | {{tp|p=33167571|t=2020. Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33122936|t=2020. Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine.|pdf=|usr=020}}
| |
| − | {{tp|p=33116761|t=2020. Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease.|pdf=|usr=020}}
| |
| − | {{tp|p=33072896|t=2020. An efficient planning technique for low dose whole lung radiation therapy for covid-19 pandemic patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33035549|t=2020. Use of protease inhibitors for the prevention of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33037151|t=2020. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.|pdf=|usr=020}}
| |
| − | {{tp|p=33028676|t=2020. Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases.|pdf=|usr=020}}
| |
| − | {{tp|p=33093202|t=2020. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33031994|t=2020. Omega-3 fatty acids in the psychological and physiological resilience against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33147503|t=2020. Host sphingolipids: Perspective immune adjuvant for controlling SARS-CoV-2 infection for managing COVID-19 disease.|pdf=|usr=020}}
| |
| − | {{tp|p=33034824|t=2020. Perspective on the Role of Antibodies and Potential Therapeutic Drugs to Combat COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33185784|t=2020. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment.|pdf=|usr=020}}
| |
| − | {{tp|p=33110944|t=2020. A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam.|pdf=|usr=020}}
| |
| − | {{tp|p=33064571|t=2020. Review of COVID-19 Antibody Therapies.|pdf=|usr=020}}
| |
| − | {{tp|p=33122172|t=2020. Repurposing Nucleoside Analogs for Human Coronaviruses.|pdf=|usr=020}}
| |
| − | {{tp|p=33122171|t=2020. Development of a simple in vitro assay to identify and evaluate nucleotide analogs against SARS-CoV-2 RNA-dependent RNA polymerase.|pdf=|usr=020}}
| |
| − | {{tp|p=33139290|t=2020. New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33113325|t=2020. Early Initiation of Extracorporeal Blood Purification Using the AN69ST (oXiris(R)) Hemofilter as a Treatment Modality for COVID-19 Patients: a Single-Centre Case Series.|pdf=|usr=020}}
| |
| − | {{tp|p=33169132|t=2020. Network Pharmacology and bioinformatics analyses identify intersection genes of niacin and COVID-19 as potential therapeutic targets.|pdf=|usr=020}}
| |
| − | {{tp|p=33054436|t=2020. Chemical composition and pharmacological mechanism of Shenfu decoction in the treatment of novel coronavirus Pneumonia (COVID-19).|pdf=|usr=020}}
| |
| − | {{tp|p=33170521|t=2020. Step toward repurposing drug discovery for COVID-19 therapeutics through in silico approach.|pdf=|usr=020}}
| |
| − | {{tp|p=33128525|t=2020. Herbal approach for the management of C0VID-19: an overview.|pdf=|usr=020}}
| |
| − | {{tp|p=33161757|t=2020. A comprehensive review on sarilumab in COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33094669|t=2020. Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease.|pdf=|usr=020}}
| |
| − | {{tp|p=33151781|t=2020. An overview on the use of antivirals for the treatment of patients with COVID19 disease.|pdf=|usr=020}}
| |
| − | {{tp|p=33121319|t=2020. SARS-CoV-2 vaccine candidates in rapid development.|pdf=|usr=020}}
| |
| − | {{tp|p=33079613|t=2020. Tocilizumab prescribing criteria for COVID-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33079612|t=2020. The Missing Link in the Covid-19 Vaccine Race.|pdf=|usr=020}}
| |
| − | {{tp|p=33064630|t=2020. Evidence and speculations: vaccines and therapeutic options for COVID-19 pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33175614|t=2020. COVID-19 coronavirus vaccine T cell epitope prediction analysis based on distributions of HLA class I loci (HLA-A, -B, -C) across global populations.|pdf=|usr=020}}
| |
| − | {{tp|p=33175602|t=2020. Impact of COVID-19 on women and children and the need for a gendered approach in vaccine development.|pdf=|usr=020}}
| |
| − | {{tp|p=33155997|t=2020. Possible role of Unani Pharmacology in COVID-19 - a narrative review.|pdf=|usr=020}}
| |
| − |
| |
| − | {{tp|p=33119257|t=2020. Profiling SARS-CoV-2 Main Protease (M(PRO)) Binding to Repurposed Drugs Using Molecular Dynamics Simulations in Classical and Neural Network-Trained Force Fields.|pdf=|usr=020}}
| |
| − | {{tp|p=33112126|t=2020. Targeting Crucial Host Factors of SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33052254|t=2020. Why PB28 Could Be a Covid 2019 Game Changer?|pdf=|usr=020}}
| |
| − | {{tp|p=33034449|t=2020. COVID-19 Vaccine Frontrunners and Their Nanotechnology Design.|pdf=|usr=020}}
| |
| − | {{tp|p=33134697|t=2020. Quantitative Structure-Activity Relationship Machine Learning Models and their Applications for Identifying Viral 3CLpro- and RdRp-Targeting Compounds as Potential Therapeutics for COVID-19 and Related Viral Infections.|pdf=|usr=020}}
| |
| − | {{tp|p=33062955|t=2020. Dipeptidyl Peptidase-4: A Potential Therapeutic Target in Diabetic Kidney Disease with SARS-CoV-2 Infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33062954|t=2020. Can Papain-like Protease Inhibitors Halt SARS-CoV-2 Replication?|pdf=|usr=020}}
| |
| − | {{tp|p=33062953|t=2020. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening.|pdf=|usr=020}}
| |
| − | {{tp|p=33062952|t=2020. An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33062951|t=2020. SARS-CoV-2 Vaccine Development: An Overview and Perspectives.|pdf=|usr=020}}
| |
| − | {{tp|p=33062950|t=2020. Potential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus Infections.|pdf=|usr=020}}
| |
| − | {{tp|p=33062949|t=2020. Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33100351|t=2020. Dinitrosyl Iron Complexes with Thiol-Containing Ligands Can Suppress Viral Infections as Donors of the Nitrosonium Cation (Hypothesis).|pdf=|usr=020}}
| |
| − | {{tp|p=33063092|t=2020. Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.|pdf=|usr=020}}
| |
| − | {{tp|p=33146673|t=2020. Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6.|pdf=|usr=020}}
| |
| − | {{tp|p=33098645|t=2020. QTc interval prolongation and life-threatening arrhythmias during hospitalization in patients with COVID-19. Results from a multi-center prospective registry.|pdf=|usr=020}}
| |
| − | {{tp|p=33036639|t=2020. Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider.|pdf=|usr=020}}
| |
| − | {{tp|p=33023646|t=2020. Anakinra: a silver lining in COVID-19?|pdf=|usr=020}}
| |
| − | {{tp|p=33023627|t=2020. TPE seems to be a treatment that may improve outcomes by effectively removing fibrin degradation products and restoring coagulation status: fact or fiction?|pdf=|usr=020}}
| |
| − | {{tp|p=33121512|t=2020. Corticosteroids in severe COVID-19: a critical view of the evidence.|pdf=|usr=020}}
| |
| − | {{tp|p=33134951|t=2020. Resolution of Coronavirus Disease 2019 Infection and Pulmonary Pathology With Nebulized DAS181: A Pilot Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33134949|t=2020. Evaluation of the Efficacy and Safety of Inhaled Epoprostenol and Inhaled Nitric Oxide for Refractory Hypoxemia in Patients With Coronavirus Disease 2019.|pdf=|usr=020}}
| |
| − | {{tp|p=33134941|t=2020. Anticytokine Therapies in Severe Coronavirus Disease 2019 Should Be Informed by Detailed Inflammatory Profiling and Specific Therapeutic Targets.|pdf=|usr=020}}
| |
| − | {{tp|p=33063037|t=2020. Convalescent Plasma Therapy in Four Critically Ill Pediatric Patients With Coronavirus Disease 2019: A Case Series.|pdf=|usr=020}}
| |
| − | {{tp|p=33063035|t=2020. Clinical Outcomes Following Tocilizumab Administration in Mechanically Ventilated Coronavirus Disease 2019 Patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33042702|t=2020. The Possibility and Cause of Relapse After Previously Recovering From COVID-19: A Systematic Review.|pdf=|usr=020}}
| |
| − | {{tp|p=33123427|t=2020. A Snapshot of the Response from UK-based Clinical Trials of Investigational Medicinal Products to COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33101806|t=2020. Subcutaneous Emphysema in Patients With COVID-19 Infection: A Report of Three Cases.|pdf=|usr=020}}
| |
| − | {{tp|p=33033686|t=2020. Icosapent Ethyl - A Successful Treatment for Symptomatic COVID-19 Infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33101792|t=2020. Bioethical Implications in Vaccine Development, a COVID-19 Challenge.|pdf=|usr=020}}
| |
| − | {{tp|p=33062500|t=2020. Ivermectin: A Closer Look at a Potential Remedy.|pdf=|usr=020}}
| |
| − | {{tp|p=33178522|t=2020. Use of Tocilizumab in COVID-19: A Systematic Review and Meta-Analysis of Current Evidence.|pdf=|usr=020}}
| |
| − | {{tp|p=33069048|t=2020. The use of copper to help prevent transmission of SARS-coronavirus and influenza viruses. A general review.|pdf=|usr=020}}
| |
| − | {{tp|p=33111813|t=2020. COVID-19 myocarditis: a case report.|pdf=|usr=020}}
| |
| − | {{tp|p=33123774|t=2020. Possible association of vitamin D status with lung involvement and outcome in patients with COVID-19: a retrospective study.|pdf=|usr=020}}
| |
| − | {{tp|p=33084959|t=2020. Micronutrients and bioactive compounds in the immunological pathways related to SARS-CoV-2 (adults and elderly).|pdf=|usr=020}}
| |
| − | {{tp|p=33115675|t=2020. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.|pdf=|usr=020}}
| |
| − | {{tp|p=33031797|t=2020. Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment.|pdf=|usr=020}}
| |
| − | {{tp|p=33145015|t=2020. Bioinformatic study to discover natural molecules with activity against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33123349|t=2020. In vitro efficacy of a copper iodine complex PPE disinfectant for SARS-CoV-2 inactivation.|pdf=|usr=020}}
| |
| − | {{tp|p=33082935|t=2020. Immunopathology of galectin-3: an increasingly promising target in COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33038452|t=2020. Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33133525|t=2020. Curcumin (a constituent of turmeric): New treatment option against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33102533|t=2020. QTc Prolongation Risk Evaluation in Female COVID-19 Patients Undergoing Chloroquine and Hydroxychloroquine With/Without Azithromycin Treatment.|pdf=|usr=020}}
| |
| − | {{tp|p=33195215|t=2020. Potential Use of Alpha-1 Anti-trypsin in the Covid-19 Treatment.|pdf=|usr=020}}
| |
| − | {{tp|p=33123533|t=2020. Designing a Network Proximity-Based Drug Repurposing Strategy for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33102489|t=2020. Mesenchymal Stem Cells and Their Extracellular Vesicles: A Potential Game Changer for the COVID-19 Crisis.|pdf=|usr=020}}
| |
| − | {{tp|p=33101215|t=2020. Stabilizing Cellular Barriers: Raising the Shields Against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33101200|t=2020. Vitamin D and Sex Differences in COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33042027|t=2020. Mediterranean Diet and COVID-19: Hypothesizing Potential Benefits in People With Diabetes.|pdf=|usr=020}}
| |
| − | {{tp|p=33193695|t=2020. Identifying Effective Antiviral Drugs Against SARS-CoV-2 by Drug Repositioning Through Virus-Drug Association Prediction.|pdf=|usr=020}}
| |
| − | {{tp|p=33193684|t=2020. Predicting the Animal Susceptibility and Therapeutic Drugs to SARS-CoV-2 Based on Spike Glycoprotein Combined With ACE2.|pdf=|usr=020}}
| |
| − | {{tp|p=33193639|t=2020. Underlying Mechanisms and Candidate Drugs for COVID-19 Based on the Connectivity Map Database.|pdf=|usr=020}}
| |
| − | {{tp|p=33173539|t=2020. Identification of Novel SARS-CoV-2 Drug Targets by Host MicroRNAs and Transcription Factors Co-regulatory Interaction Network Analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33195334|t=2020. IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections.|pdf=|usr=020}}
| |
| − | {{tp|p=33195318|t=2020. Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?|pdf=|usr=020}}
| |
| − | {{tp|p=33195402|t=2020. Determine the Potential Epitope Based Peptide Vaccine Against Novel SARS-CoV-2 Targeting Structural Proteins Using Immunoinformatics Approaches.|pdf=|usr=020}}
| |
| − | {{tp|p=33195397|t=2020. Drug Weaponry to Fight Against SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33134311|t=2020. Can CRISPR/Cas Technology Be a Felicitous Stratagem Against the COVID-19 Fiasco? Prospects and Hitches.|pdf=|usr=020}}
| |
| − | {{tp|p=33134310|t=2020. Discovery of Potential Flavonoid Inhibitors Against COVID-19 3CL Proteinase Based on Virtual Screening Strategy.|pdf=|usr=020}}
| |
| − | {{tp|p=33132558|t=2020. Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers.|pdf=|usr=020}}
| |
| − | {{tp|p=33078736|t=2020. The narrow road to a COVID-19 vaccine.|pdf=|usr=020}}
| |
| − | {{tp|p=33078733|t=2020. Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33075484|t=2020. Hydroxychloroquine and QTc prolongation in patients with COVID-19: A systematic review and meta-analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33191178|t=2020. Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2.|pdf=|usr=020}}
| |
| − | {{tp|p=33189613|t=2020. Exploring the multifocal therapeutic approaches in COVID-19: A ray of hope.|pdf=|usr=020}}
| |
| − | {{tp|p=33182059|t=2020. Correlation between premorbid IL-6 levels and COVID-19 mortality: Potential role for Vitamin D.|pdf=|usr=020}}
| |
| − | {{tp|p=33182040|t=2020. Lower levels of vitamin D are associated with SARS-CoV-2 infection and mortality in the Indian population: An observational study.|pdf=|usr=020}}
| |
| − | {{tp|p=33166692|t=2020. LPD-12, a Promising Lipopeptide to Control COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33152450|t=2020. Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial.|pdf=|usr=020}}
| |
| − | {{tp|p=33189891|t=2020. Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs.|pdf=|usr=020}}
| |
| − | {{tp|p=33166694|t=2020. Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33164789|t=2020. Frequency of Long QT in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine: A Meta-analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33122096|t=2020. COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study.|pdf=|usr=020}}
| |
| − | {{tp|p=33075513|t=2020. Preparation and physicochemical stability of 50 mg/mL hydroxychloroquine oral suspension in SyrSpend() SF PH4 (dry).|pdf=|usr=020}}
| |
| − | {{tp|p=33075512|t=2020. Methylene blue inhibits replication of SARS-CoV-2 in vitro.|pdf=|usr=020}}
| |
| − | {{tp|p=33045354|t=2020. Projected supportive effects of Pycnogenol() in patients suffering from multi-dimensional health impairments after a SARS-CoV2 infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33045350|t=2020. Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33075384|t=2020. Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problem.|pdf=|usr=020}}
| |
| − | {{tp|p=33035673|t=2020. Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness.|pdf=|usr=020}}
| |
| − | {{tp|p=33091154|t=2020. Vaccine design based on 16 epitopes of SARS-CoV-2 spike protein.|pdf=|usr=020}}
| |
| − | {{tp|p=33106779|t=2020. Phase 3 Randomized Controlled Trials on Exclusion of Participants with Kidney Disease in COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33129421|t=2020. Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties.|pdf=|usr=020}}
| |
| − | {{tp|p=33131609|t=2020. Human recombinant soluble ACE2 in severe COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33163976|t=2020. Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians.|pdf=|usr=020}}
| |
| − | {{tp|p=33088576|t=2020. Critical reappraisal of remdesivir investigational trials in COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33088574|t=2020. Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world.|pdf=|usr=020}}
| |
| − | {{tp|p=33072335|t=2020. Role of micronutrients in the management of coronavirus disease 2019.|pdf=|usr=020}}
| |
| − | {{tp|p=33037698|t=2020. Potential roles of medicinal plants for the treatment of viral diseases focusing on COVID-19: A review.|pdf=|usr=020}}
| |
| − | {{tp|p=33034398|t=2020. A role for quercetin in coronavirus disease 2019 (COVID-19).|pdf=|usr=020}}
| |
| − | {{tp|p=33047412|t=2020. Revisiting pharmacological potentials of Nigella sativa seed: A promising option for COVID-19 prevention and cure.|pdf=|usr=020}}
| |
| − | {{tp|p=33111431|t=2020. N-Terminomics for the Identification of In Vitro Substrates and Cleavage Site Specificity of the SARS-CoV-2 Main Protease.|pdf=|usr=020}}
| |
| − | {{tp|p=33030073|t=2020. The benefits of Vitamin D in the COVID-19 pandemic: biochemical and immunological mechanisms.|pdf=|usr=020}}
| |
| − | {{tp|p=33125298|t=2020. Role of vitamin D in pathogenesis and severity of COVID-19 infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33111980|t=2020. Ozone as adjuvant support in the treatment of COVID-19: A preliminary report of probiozovid trial.|pdf=|usr=020}}
| |
| − | {{tp|p=33107628|t=2020. A case of COVID-19, with cytokine storm, treated by consecutive use of therapeutic plasma exchange followed by convalescent plasma transfusion: A case report.|pdf=|usr=020}}
| |
| − | {{tp|p=33107607|t=2020. Corticosteroids for COVID-19 patients requiring oxygen support? Yes, but not for everyone: Effect of corticosteroids on mortality and intensive care unit admission in patients with COVID-19 according to patients' oxygen requirements.|pdf=|usr=020}}
| |
| − | {{tp|p=33073355|t=2020. Pathogenesis-directed therapy of 2019 novel coronavirus disease.|pdf=|usr=020}}
| |
| − | {{tp|p=33113210|t=2020. Is there a role for childhood vaccination against COVID-19?|pdf=|usr=020}}
| |
| − | {{tp|p=33025993|t=2020. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.|pdf=|usr=020}}
| |
| − | {{tp|p=32985017|t=2020. Natural products for COVID-19 prevention and treatment regarding to previous coronavirus infections and novel studies.|pdf=|usr=020}}
| |
| − | {{tp|p=32964551|t=2020. Aframomum melegueta secondary metabolites exhibit polypharmacology against SARS-CoV-2 drug targets: in vitro validation of furin inhibition.|pdf=|usr=020}}
| |
| − | {{tp|p=33159391|t=2020. A pharmacology-based comprehensive review on medicinal plants and phytoactive constituents possibly effective in the management of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=32892684|t=2020. Selective inhibition of thromboinflammation in COVID-19 by Btk inhibitors.|pdf=|usr=020}}
| |
| − | {{tp|p=33077403|t=2020. Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection?|pdf=|usr=020}}
| |
| − | {{tp|p=33050993|t=2020. Thalidomide Should Be Tested as a Therapeutic Option in COVID-19 Pneumonia.|pdf=|usr=020}}
| |
| − | {{tp|p=33155515|t=2020. Saporin, a Polynucleotide-Adenosine Nucleosidase, May Be an Efficacious Therapeutic Agent for SARS-CoV-2 Infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33068341|t=2020. [Moxibustion therapy in prevention and treatment of coronavirus disease 2019 (COVID-19): construction and application of non-contact diagnosis and treatment mode].|pdf=|usr=020}}
| |
| − | {{tp|p=33081907|t=2020. [Possibility of mesenchymal stem cell transplantation in the treatment of coronavirus disease 2019].|pdf=|usr=020}}
| |
| − | {{tp|p=33081905|t=2020. [Metformin: one of the possible options to reduce the mortality of severe coronavirus disease 2019?]|pdf=|usr=020}}
| |
| − | {{tp|p=32912403|t=2020. [A single arm clinical study of 86 patients with common type of coronavirus disease 2019 treated by integrated traditional Chinese and Western medicine: multicenter case observation from 7 designated hospitals in Henan Province].|pdf=|usr=020}}
| |
| − | {{tp|p=32912400|t=2020. [Whole-process prevention and treatment model of traditional Chinese medicine for coronavirus disease 2019 epidemics].|pdf=|usr=020}}
| |
| − |
| |
| − | {{tp|p=33157066|t=2020. Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG.|pdf=|usr=020}}
| |
| − | {{tp|p=33174766|t=2020. SARS-CoV-2: Influence of phosphate and magnesium, moderated by vitamin D, on energy (ATP)-metabolism and on severity of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33161152|t=2020. Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019.|pdf=|usr=020}}
| |
| − | {{tp|p=33169088|t=2020. Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series.|pdf=|usr=020}}
| |
| − | {{tp|p=32954790|t=2020. Saudi Heart Rhythm Society Task Force on Management of Potential Arrhythmogenicity Associated with Pharmacotherapy for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33178779|t=2020. Comprehensive review on the prevailing COVID-19 therapeutics and the potential of repurposing SARS-CoV-1 candidate drugs to target SARS-CoV-2 as a fast-track treatment and prevention option.|pdf=|usr=020}}
| |
| − | {{tp|p=33136210|t=2020. Tetracycline and viruses: a possible treatment for COVID-19?|pdf=|usr=020}}
| |
| − | {{tp|p=33093748|t=2020. Remdesivir for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33032673|t=2020. Mechanisms linking the human gut microbiome to prophylactic and treatment strategies for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33106765|t=2020. Ayurveda and Allopathic Therapeutic Strategies in Coronavirus Pandemic Treatment 2020.|pdf=|usr=020}}
| |
| − | {{tp|p=33052305|t=2020. Challenges and future directions of potential natural products leads against 2019-nCoV outbreak.|pdf=|usr=020}}
| |
| − | {{tp|p=33180190|t=2020. Steroid administration in the Covid-19 era; timing does matter!|pdf=|usr=020}}
| |
| − | {{tp|p=33118012|t=2020. New data on soluble ACE2 in patients with atrial fibrillation reveal potential value for treatment of patients with COVID-19 and cardiovascular disease.|pdf=|usr=020}}
| |
| − | {{tp|p=33135047|t=2020. EFFECT oF STATIN THERAPY oN SARS-CoV-2 INFECTION-RELATED.|pdf=|usr=020}}
| |
| − | {{tp|p=33033717|t=2020. Prepare for the Future: Dissecting the Spike to Seek Broadly Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses.|pdf=|usr=020}}
| |
| − | {{tp|p=33117121|t=2020. Would Repurposing Minocycline Alleviate Neurologic Manifestations of COVID-19?|pdf=|usr=020}}
| |
| − | {{tp|p=33195371|t=2020. Covid-19 Quarantine: Impact of Lifestyle Behaviors Changes on Endothelial Function and Possible Protective Effect of Beetroot Juice.|pdf=|usr=020}}
| |
| − | {{tp|p=33195370|t=2020. Clinical Impact Potential of Supplemental Nutrients as Adjuncts of Therapy in High-Risk COVID-19 for Obese Patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33195363|t=2020. Potential Role of Vitamin B6 in Ameliorating the Severity of COVID-19 and Its Complications.|pdf=|usr=020}}
| |
| − | {{tp|p=33102511|t=2020. Thrombosis and COVID-19: The Potential Role of Nutrition.|pdf=|usr=020}}
| |
| − | {{tp|p=33072589|t=2020. Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia.|pdf=|usr=020}}
| |
| − | {{tp|p=33101042|t=2020. The Regulatory Challenges for Drug Repurposing During the Covid-19 Pandemic: The Italian Experience.|pdf=|usr=020}}
| |
| − | {{tp|p=33101037|t=2020. The Important Role of Volatile Components From a Traditional Chinese Medicine Dayuan-Yin Against the COVID-19 Pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33101023|t=2020. Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19).|pdf=|usr=020}}
| |
| − | {{tp|p=33071794|t=2020. COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy?|pdf=|usr=020}}
| |
| − | {{tp|p=33071786|t=2020. Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome.|pdf=|usr=020}}
| |
| − | {{tp|p=33071781|t=2020. Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33071777|t=2020. Lian Hua Qing Wen Capsules, a Potent Epithelial Protector in Acute Lung Injury Model, Block Proapoptotic Communication Between Macrophages, and Alveolar Epithelial Cells.|pdf=|usr=020}}
| |
| − | {{tp|p=33041830|t=2020. Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena.|pdf=|usr=020}}
| |
| − | {{tp|p=33041827|t=2020. Systems Pharmacology and Verification of ShenFuHuang Formula in Zebrafish Model Reveal Multi-Scale Treatment Strategy for Septic Syndrome in COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33041819|t=2020. The Potential of Antiviral Peptides as COVID-19 Therapeutics.|pdf=|usr=020}}
| |
| − | {{tp|p=33041814|t=2020. Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives.|pdf=|usr=020}}
| |
| − | {{tp|p=33041797|t=2020. In Silico Prediction of Molecular Targets of Astragaloside IV for Alleviation of COVID-19 Hyperinflammation by Systems Network Pharmacology and Bioinformatic Gene Expression Analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33192602|t=2020. Beta-Adrenergic Receptor Stimulation Modulates the Cellular Proarrhythmic Effects of Chloroquine and Azithromycin.|pdf=|usr=020}}
| |
| − | {{tp|p=33178033|t=2020. Physical Exercise and the Renin Angiotensin System: Prospects in the COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33135113|t=2020. Ibuprofen and NSAID Use in COVID-19 Infected Patients Is Not Associated with Worse Outcomes: A Prospective Cohort Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33171852|t=2020. Cardiovascular Active Peptides of Marine Origin with ACE Inhibitory Activities: Potential Role as Anti-Hypertensive Drugs and in Prevention of SARS-CoV-2 Infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33158276|t=2020. Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2.|pdf=|usr=020}}
| |
| − | {{tp|p=33187101|t=2020. Exposome and Immunity Training: How Pathogen Exposure Order Influences Innate Immune Cell Lineage Commitment and Function.|pdf=|usr=020}}
| |
| − | {{tp|p=33192207|t=2020. Designing of Nucleocapsid Protein Based Novel Multi-epitope Vaccine Against SARS-COV-2 Using Immunoinformatics Approach.|pdf=|usr=020}}
| |
| − | {{tp|p=33120196|t=2020. Ebselen, a new candidate therapeutic against SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33131033|t=2020. Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience.|pdf=|usr=020}}
| |
| − | {{tp|p=33063792|t=2020. Molecular determinants of vascular transport of dexamethasone in COVID-19 therapy.|pdf=|usr=020}}
| |
| − | {{tp|p=33196058|t=2020. Possible protective role of 17beta-estradiol against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33077329|t=2020. Nitric Oxide Ventilation Improves Recirculation and Right Ventricular Function During Veno-Venous Extracorporeal Membrane Oxygenation in a COVID-19 Patient.|pdf=|usr=020}}
| |
| − | {{tp|p=33189533|t=2020. Interleukin-6 Antagonist Tocilizumab to Treat Critically Ill Coronavirus Disease 2019 Patients With Cytokine Release Syndrome: A Case Series.|pdf=|usr=020}}
| |
| − | {{tp|p=33091590|t=2020. Molecular characterization, pathogen-host interaction pathway and in silico approaches for vaccine design against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33166894|t=2020. A preparative chiral separation of hydroxychloroquine using supercritical fluid chromatography.|pdf=|usr=020}}
| |
| − | {{tp|p=33041506|t=2020. Evaluation of the nutritional status in patients with COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33188624|t=2020. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33029275|t=2020. Low-Flow Nasal Cannula Hydrogen Therapy.|pdf=|usr=020}}
| |
| − | {{tp|p=33029269|t=2020. Could Estrogen Protect Women From COVID-19?|pdf=|usr=020}}
| |
| − | {{tp|p=33099370|t=2020. Reissuing the sigma receptors for SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33194123|t=2020. Back to basics: review on vitamin D and respiratory viral infections including COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33103220|t=2020. Supervised molecular dynamics for exploring the druggability of the SARS-CoV-2 spike protein.|pdf=|usr=020}}
| |
| − | {{tp|p=33034007|t=2020. Combining fragment docking with graph theory to improve ligand docking for homology model structures.|pdf=|usr=020}}
| |
| − | {{tp|p=33038449|t=2020. Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33102263|t=2020. Biological response modifier glucan through balancing of blood glucose may have a prophylactic potential in COVID-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33058941|t=2020. Do hydrogen peroxide mouthwashes have a virucidal effect? A systematic review.|pdf=|usr=020}}
| |
| − | {{tp|p=33168456|t=2020. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.|pdf=|usr=020}}
| |
| − | {{tp|p=33109497|t=2020. Computational studies reveal mechanism by which quinone derivatives can inhibit SARS-CoV-2. Study of embelin and two therapeutic compounds of interest, methyl prednisolone and dexamethasone.|pdf=|usr=020}}
| |
| − | {{tp|p=33054210|t=2020. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33030607|t=2020. Intravenous immunoglobulin therapy in COVID-19-related encephalopathy.|pdf=|usr=020}}
| |
| − | {{tp|p=33155635|t=2020. Letter to the Editor: Is Vitamin D One of the Key Elements in COVID-19 Days?|pdf=|usr=020}}
| |
| − | {{tp|p=33155630|t=2020. Relation of Dietary Factors with Infection and Mortality Rates of COVID-19 across the World.|pdf=|usr=020}}
| |
| − | {{tp|p=33109269|t=2020. Povidone-iodine solution as SARS-CoV-2 prophylaxis for procedures of the upper aerodigestive tract a theoretical framework.|pdf=|usr=020}}
| |
| − | {{tp|p=33182350|t=2020. Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19?|pdf=|usr=020}}
| |
| − | {{tp|p=33115823|t=2020. A Biomarker-Centric Approach to Drug Discovery and Development: Lessons Learned from the COVID-19 Pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33095007|t=2020. Antiviral Peptides as Promising Therapeutics against SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33104327|t=2020. COSMO-RS-Based Descriptors for the Machine Learning-Enabled Screening of Nucleotide Analogue Drugs against SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33092337|t=2020. Immune response to physical exercise: evidence to take into account during the coronavirus disease (COVID-19) pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33162308|t=2020. Could Bronchial Artery Embolization Be a Modality for Treating Severe Acute Respiratory Syndrome Coronavirus 2?|pdf=|usr=020}}
| |
| − | {{tp|p=33102950|t=2020. The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33163977|t=2020. Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review.|pdf=|usr=020}}
| |
| − | {{tp|p=32896291|t=2020. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.|pdf=|usr=020}}
| |
| − | {{tp|p=32896290|t=2020. COVID-19 vaccines: early success and remaining challenges.|pdf=|usr=020}}
| |
| − | {{tp|p=32971041|t=2020. Safety and efficacy of the Russian COVID-19 vaccine: more information needed.|pdf=|usr=020}}
| |
| − | {{tp|p=33172794|t=2020. Drug-induced QT prolongation in COVID-19 pneumonia: influence on in-hospital survival.|pdf=|usr=020}}
| |
| − | {{tp|p=33179954|t=2020. Access considerations for a COVID-19 vaccine for South Africa.|pdf=|usr=020}}
| |
| − | {{tp|p=33140636|t=2020. Toward COVID-19 Therapeutics: A Viewpoint from the Nonprotein Amino Acid Based Synthetic Peptide Design Approach.|pdf=|usr=020}}
| |
| − | {{tp|p=33120507|t=2020. Response to Comment on Considering the Effects of Microbiome and Diet on SARS-CoV-2 Infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33120503|t=2020. Comment on Considering the Effects of Microbiome and Diet on SARS-CoV-2 Infection: Nanotechnology Roles.|pdf=|usr=020}}
| |
| − | {{tp|p=33177042|t=2020. Covid-19: FDA authorises neutralising antibody bamlanivimab for non-admitted patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33104430|t=2020. Nutritional Care in Relation to COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33112664|t=2020. Caution warranted for low-dose radiation therapy for Covid-19.|pdf=|usr=020}}
| |
| − | {{tp|p=32915766|t=2020. Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood.|pdf=|usr=020}}
| |
| − | {{tp|p=33090501|t=2020. Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33022386|t=2020. Curb complement to cure COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33144402|t=2020. Rationale for the use of sphingosine analogues in COVID-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33113246|t=2020. Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development.|pdf=|usr=020}}
| |
| − | {{tp|p=33085221|t=2020. Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID-19: A Retrospective Multicenter Study in the United States.|pdf=|usr=020}}
| |
| − | {{tp|p=33135382|t=2020. A Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33048372|t=2020. Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data.|pdf=|usr=020}}
| |
| − | {{tp|p=32936948|t=2020. Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19 infection to improve patient outcomes and to protect healthcare workers treating them.|pdf=|usr=020}}
| |
| − | {{tp|p=32936947|t=2020. Antimicrobial mouthwashes (gargling) and nasal sprays to protect healthcare workers when undertaking aerosol-generating procedures (AGPs) on patients without suspected or confirmed COVID-19 infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33044747|t=2020. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.|pdf=|usr=020}}
| |
| − | {{tp|p=33148952|t=2020. Harmonizing Heterogeneous Endpoints in Coronavirus Disease 2019 Trials Without Loss of Information.|pdf=|usr=020}}
| |
| − | {{tp|p=33031192|t=2020. Angiotensin II Administration in Patients with COVID-19 Shock.|pdf=|usr=020}}
| |
| − | {{tp|p=33146028|t=2020. Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33023358|t=2020. Making a case for using gammadelta T cells against SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33059567|t=2020. Cardiac Complications Attributed to Hydroxychloroquine: A systematic review of the Literature Pre-COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33023445|t=2020. Epidemiological Situation and Efficacy of Dexamethasone for the treatment planning of COVID-19: A perspective review.|pdf=|usr=020}}
| |
| − | {{tp|p=33073612|t=2020. Infusion of HLA-matched and static magnetic field-exposed allogenic lymphocytes treating lymphocytopenia and cytokine storm syndrome: A treatment proposal for COVID-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33143478|t=2020. Role of povidone iodine in ophthalmic clinical practice amidst COVID-19 pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33047989|t=2020. Could bacteriophages be the answer to the COVID-19 crisis?|pdf=|usr=020}}
| |
| − | {{tp|p=33164589|t=2020. Nanotechnology-based promising strategies for the management of COVID-19: current development and constraints.|pdf=|usr=020}}
| |
| − | {{tp|p=33146561|t=2020. Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation.|pdf=|usr=020}}
| |
| − | {{tp|p=33172313|t=2020. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.|pdf=|usr=020}}
| |
| − | {{tp|p=33144490|t=2020. Classical Drug Digitoxin Inhibits Influenza Cytokine Storm, With Implications for Covid-19 Therapy.|pdf=|usr=020}}
| |
| − | {{tp|p=33154234|t=2020. Effect of chloroquine and hydroxychloroquine on COVID-19 virological outcomes: An updated meta-analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33154232|t=2020. Convalescent plasma - Is it useful for treating SARS Co-V2 infection?|pdf=|usr=020}}
| |
| − | {{tp|p=33084153|t=2020. A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States.|pdf=|usr=020}}
| |
| − |
| |
| − | {{tp|p=33161397|t=2020. Is G-CSF Dangerous in COVID-19: Why Not Use GM-CSF?|pdf=|usr=020}}
| |
| − | {{tp|p=33173601|t=2020. Preclinical Studies of Immunogenity, Protectivity, and Safety of the Combined Vector Vaccine for Prevention of the Middle East Respiratory Syndrome.|pdf=|usr=020}}
| |
| − | {{tp|p=33072499|t=2020. Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening.|pdf=|usr=020}}
| |
| − | {{tp|p=33116249|t=2020. Identification of SARS-CoV-2 entry inhibitors among already approved drugs.|pdf=|usr=020}}
| |
| − | {{tp|p=33110240|t=2020. Hypoxia, HIF-1alpha, and COVID-19: from pathogenic factors to potential therapeutic targets.|pdf=|usr=020}}
| |
| − | {{tp|p=33041326|t=2020. Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice.|pdf=|usr=020}}
| |
| − | {{tp|p=33081436|t=2020. Role of vitamin C in critically ill patients with COVID-19: is it effective?|pdf=|usr=020}}
| |
| − | {{tp|p=32837898|t=2020. The effects of N-acetyl cysteine on acute viral respiratory infections in humans: A rapid review.|pdf=|usr=020}}
| |
| − | {{tp|p=32837896|t=2020. The effects of vitamin D on acute viral respiratory infections: A rapid review.|pdf=|usr=020}}
| |
| − | {{tp|p=32837892|t=2020. Multivitamins for acute respiratory tract infections: a rapid review.|pdf=|usr=020}}
| |
| − | {{tp|p=33111375|t=2020. SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination.|pdf=|usr=020}}
| |
| − | {{tp|p=33031060|t=2020. Efficacy and safety of tocilizumab in COVID-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33101838|t=2020. Anti-inflammatory substances from onions could be an option for treatment of COVID-19-a hypothesis.|pdf=|usr=020}}
| |
| − | {{tp|p=33121978|t=2020. Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33164793|t=2020. More Good News on Statins and COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33041111|t=2020. SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence.|pdf=|usr=020}}
| |
| − | {{tp|p=33168381|t=2020. Dexmedetomidine in COVID-19: probing promises with prudence!|pdf=|usr=020}}
| |
| − | {{tp|p=33071096|t=2020. Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians.|pdf=|usr=020}}
| |
| − | {{tp|p=33146236|t=2020. Cardiac glycosides and COVID-19: would it be a promising therapeutic approach?|pdf=|usr=020}}
| |
| − | {{tp|p=33115684|t=2020. COVID-19, steroids and other immunomodulators: The jigsaw is not complete.|pdf=|usr=020}}
| |
| − | {{tp|p=33096261|t=2020. Anti-infective therapy against SARS-CoV-2: some light at the end of the tunnel?|pdf=|usr=020}}
| |
| − | {{tp|p=33096260|t=2020. Vaccines against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33059104|t=2020. Nutritional support for critically ill patients with COVID-19: New strategy for a new disease?|pdf=|usr=020}}
| |
| − | {{tp|p=33173857|t=2020. A novel approach to spinal anaesthesia to avoid aerosol-generating procedures in a patient with COVID-19 presenting for laser prostate surgery.|pdf=|usr=020}}
| |
| − | {{tp|p=33121927|t=2020. The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro.|pdf=|usr=020}}
| |
| − | {{tp|p=33082858|t=2020. Examining the effector mechanisms of Xuebijing injection on COVID-19 based on network pharmacology.|pdf=|usr=020}}
| |
| − | {{tp|p=33048300|t=2020. Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?|pdf=|usr=020}}
| |
| − | {{tp|p=33123616|t=2020. The role of nicotinic receptors in SARS-CoV-2 receptor ACE2 expression in intestinal epithelia.|pdf=|usr=020}}
| |
| − | {{tp|p=33149560|t=2020. Targeting the GRP78-Dependant SARS-CoV-2 Cell Entry by Peptides and Small Molecules.|pdf=|usr=020}}
| |
| − | {{tp|p=33031540|t=2020. Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33032282|t=2020. Sudden Cardiac Death in Haemodialysis Patients under Hydroxychloroquine Treatment for COVID-19: A Report of Two Cases.|pdf=|usr=020}}
| |
| − | {{tp|p=33171470|t=2020. Hemoperfusion as a Potential Treatment for Critically Ill COVID-19 Patients with Cytokine Storm.|pdf=|usr=020}}
| |
| − | {{tp|p=33176880|t=2020. Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as M(Pro) inhibitors of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).|pdf=|usr=020}}
| |
| − | {{tp|p=33093056|t=2020. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).|pdf=|usr=020}}
| |
| − | {{tp|p=33144278|t=2020. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).|pdf=|usr=020}}
| |
| − | {{tp|p=33173650|t=2020. Potential Role of Xylitol Plus Grapefruit Seed Extract Nasal Spray Solution in COVID-19: Case Series.|pdf=|usr=020}}
| |
| − | {{tp|p=33089050|t=2020. Drug-induced 'Torsade de Pointes' in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report.|pdf=|usr=020}}
| |
| − | {{tp|p=33125946|t=2020. Repurposing anticancer drugs for the management of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33194871|t=2020. Late Worsening of COVID-19 Pneumonia: Successful Treatment with Ruxolitinib and Steroid.|pdf=|usr=020}}
| |
| − | {{tp|p=33123934|t=2020. Delayed hospital admission and high-dose corticosteroids potentially prolong SARS-CoV-2 RNA detection duration of patients with COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33083917|t=2020. High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study.|pdf=|usr=020}}
| |
| − | {{tp|p=33168957|t=2020. Nutritional strategies for the rehabilitation of COVID-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33051695|t=2020. Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies.|pdf=|usr=020}}
| |
| − | {{tp|p=33163124|t=2020. Exploring the potential therapeutic effect of traditional Chinese medicine on coronavirus disease 2019 (COVID-19) through a combination of data mining and network pharmacology analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33132004|t=2020. Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness.|pdf=|usr=020}}
| |
| − | {{tp|p=33127218|t=2020. Does hydroxychloroquine reduce mortality for COVID-19?|pdf=|usr=020}}
| |
| − | {{tp|p=33162299|t=2020. Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33164596|t=2020. The risk of induced cancer and ischemic heart disease following low dose lung irradiation for COVID-19: estimation based on a virtual case.|pdf=|usr=020}}
| |
| − | {{tp|p=33057452|t=2020. Potential bioactive glycosylated flavonoids as SARS-CoV-2 main protease inhibitors: A molecular docking and simulation studies.|pdf=|usr=020}}
| |
| − | {{tp|p=33057358|t=2020. Design of novel multiepitope constructs-based peptide vaccine against the structural S, N and M proteins of human COVID-19 using immunoinformatics analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33031409|t=2020. Therapeutic effects of adenosine in high flow 21% oxygen aereosol in patients with Covid19-pneumonia.|pdf=|usr=020}}
| |
| − | {{tp|p=33027297|t=2020. BCG epidemiology supports its protection against COVID-19? A word of caution.|pdf=|usr=020}}
| |
| − | {{tp|p=33119725|t=2020. "Trained immunity" from Mycobacterium spp. exposure or BCG vaccination and COVID-19 outcomes.|pdf=|usr=020}}
| |
| − | {{tp|p=33137165|t=2020. The role of cysteine peptidases in coronavirus cell entry and replication: The therapeutic potential of cathepsin inhibitors.|pdf=|usr=020}}
| |
| − | {{tp|p=33119227|t=2020. Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend?|pdf=|usr=020}}
| |
| − | {{tp|p=33119226|t=2020. Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend? Authors' reply.|pdf=|usr=020}}
| |
| − | {{tp|p=33183986|t=2020. A patient affected by critical COVID-19 pneumonia, successfully treated with convalescent plasma.|pdf=|usr=020}}
| |
| − | {{tp|p=33162341|t=2020. Potential of therapeutic plasmapheresis in treatment of COVID-19 patients: Immunopathogenesis and coagulopathy.|pdf=|usr=020}}
| |
| − | {{tp|p=33153902|t=2020. SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation.|pdf=|usr=020}}
| |
| − | {{tp|p=33071174|t=2020. A case of COVID-19 Convalescent Plasma Donation in Greece: Directed donation for compassionate use in the donor's critically ill father.|pdf=|usr=020}}
| |
| − | {{tp|p=33073202|t=2020. Ivermectin, Famotidine, and Doxycycline: A Suggested Combinatorial Therapeutic for the Treatment of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33073200|t=2020. Heme/Hemeoxygenase-1 System Is a Potential Therapeutic Intervention for COVID-19 Patients with Severe Complications.|pdf=|usr=020}}
| |
| − | {{tp|p=33073199|t=2020. Achilles' Heel of SARS-CoV-2 Structure.|pdf=|usr=020}}
| |
| − | {{tp|p=33073198|t=2020. Therapeutically Targeted Destabilization of the Quaternary Structure of the Spike Protein in the Dominant G614 Strain of SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33170176|t=2020. A pilot study on the preventative potential of alpha-cyclodextrin and hydroxytyrosol against SARS-CoV-2 transmission.|pdf=|usr=020}}
| |
| − | {{tp|p=33170175|t=2020. Pilot study for the evaluation of safety profile of a potential inhibitor of SARS-CoV-2 endocytosis.|pdf=|usr=020}}
| |
| − | {{tp|p=33170174|t=2020. Natural compounds as inhibitors of SARS-CoV-2 endocytosis: A promising approach against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33151168|t=2021. Sitagliptin: a potential drug for the treatment of COVID-19?|pdf=|usr=020}}
| |
| − | {{tp|p=33151166|t=2021. Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies.|pdf=|usr=020}}
| |
| − | {{tp|p=33148006|t=2020. Development of Rapid Advice Guidelines for the Treatment of Coronavirus Disease 2019 with Traditional Chinese Medicine.|pdf=|usr=020}}
| |
| − | {{tp|p=33148005|t=2020. Traditional Chinese Medicine Formulation Therapy in the Treatment of Coronavirus Disease 2019 (COVID-19).|pdf=|usr=020}}
| |
| − | {{tp|p=33136567|t=2020. Lopinavir-Ritonavir and Liver Involvement in Patients With COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33105209|t=2020. Do Low Vitamin D Levels Increase COVID-19 Risk?|pdf=|usr=020}}
| |
| − | {{tp|p=33085908|t=2020. COVID-19, Hypercoagulability and Cautiousness with Convalescent Plasma.|pdf=|usr=020}}
| |
| − | {{tp|p=33093359|t=2020. Aspirin Use is Associated with Decreased Mechanical Ventilation, ICU Admission, and In-Hospital Mortality in Hospitalized Patients with COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33049143|t=2020. Ethnic and Sex Representation in Trials Shaping Best Practice for Covid-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33166179|t=2020. Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial.|pdf=|usr=020}}
| |
| − | {{tp|p=33093065|t=2020. Covid-19: Vaccine trials need more transparency to enable scrutiny and earn public trust, say experts.|pdf=|usr=020}}
| |
| − | {{tp|p=33093025|t=2020. Convalescent plasma is ineffective for covid-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33093016|t=2020. Covid-19: Human challenge studies will see people purposefully infected with virus.|pdf=|usr=020}}
| |
| − | {{tp|p=33087398|t=2020. Will covid-19 vaccines save lives? Current trials aren't designed to tell us.|pdf=|usr=020}}
| |
| − | {{tp|p=33087395|t=2020. Covid-19 vaccine trial protocols released.|pdf=|usr=020}}
| |
| − | {{tp|p=33077424|t=2020. Covid-19: Remdesivir has little or no impact on survival, WHO trial shows.|pdf=|usr=020}}
| |
| − | {{tp|p=33130588|t=2020. Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33038909|t=2020. Targeted delivery of CRISPR/Cas13 as a promising therapeutic approach to treat SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33109039|t=2020. The Binding of Remdesivir to SARS-CoV-2 RNA-Dependent RNA polymerase May Pave The Way Towards the Design of Potential Drugs for COVID-19 Treatment.|pdf=|usr=020}}
| |
| − | {{tp|p=33148151|t=2020. Insights from Pharmaceutical Biotechnology into Phenolic Biopharmaceuticals against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33176643|t=2020. Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach Against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33176642|t=2020. Potential implications of black seed and its principal constituent Thymoquinone in the treatment of COVID-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33023440|t=2020. Quinoline-based Compounds as Key Candidates to Tackle Drug Discovery Programs of Microbicidal Agents.|pdf=|usr=020}}
| |
| − | {{tp|p=33100195|t=2020. COVID-19 Vaccines on Clinical Trials and their Mode of Action for Immunity against the Virus.|pdf=|usr=020}}
| |
| − | {{tp|p=33059564|t=2020. The undiscovered potential of essential oils for treating SARS-CoV-2 (COVID- 19).|pdf=|usr=020}}
| |
| − | {{tp|p=33155905|t=2020. Properties of Ethno-Medicinal Plants and Their Bioactives-Possible Use for Prevention and Treatment of COVID-19: A Review.|pdf=|usr=020}}
| |
| − | {{tp|p=33155902|t=2020. Current landscape of natural products against coronaviruses: perspectives in COVID-19 treatment and antiviral mechanism.|pdf=|usr=020}}
| |
| − | {{tp|p=33176644|t=2020. Are Hsp90 inhibitors good candidates against Covid-19?|pdf=|usr=020}}
| |
| − | {{tp|p=33094291|t=2020. Luminespib counteracts the Kifunensine-induced lung endothelial barrier dysfunction.|pdf=|usr=020}}
| |
| − | {{tp|p=33045970|t=2020. Stem Cell Therapy: A Promising Approach in Treatment of COVID 19.|pdf=|usr=020}}
| |
| − | {{tp|p=33153418|t=2020. Most Promising Compounds for Treating COVID-19 and Recent Trends in Antimicrobial & Antifungal Agents.|pdf=|usr=020}}
| |
| − | {{tp|p=33040729|t=2020. Importance of Environmental Factors on Production of Computationally- Defined Natural Molecules against COVID-19 Pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33030464|t=2020. What is holding back the development of antiviral metallodrugs? A literature overview and implications for SARS-CoV-2 therapeutics and future viral outbreaks.|pdf=|usr=020}}
| |
| − | {{tp|p=33107144|t=2020. COVID-19: Topical agents and therapeutic prevention of nasal viral acquisition.|pdf=|usr=020}}
| |
| − | {{tp|p=33033068|t=2020. Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards.|pdf=|usr=020}}
| |
| − | {{tp|p=33054486|t=2020. Deciphering Vaccines for COVID-19: where do we stand today?|pdf=|usr=020}}
| |
| − | {{tp|p=33106053|t=2020. Biochemical and immunological aspects of COVID-19 infection and therapeutical intervention of oral low dose cytokine therapy: a systematic review.|pdf=|usr=020}}
| |
| − | {{tp|p=33152797|t=2020. Rapid improvement of a critically ill obstetric patient with SARS-CoV-2 infection after administration of convalescent plasma.|pdf=|usr=020}}
| |
| − | {{tp|p=33029911|t=2020. A multiscale absorption and transit model for oral delivery of hydroxychloroquine: Pharmacokinetic modeling and intestinal concentration prediction to assess toxicity and drug-induced damage in healthy subjects.|pdf=|usr=020}}
| |
| − | {{tp|p=33143519|t=2020. Adverse drug reactions associated with concurrent acute psychiatric treatment and Covid-19 drug therapy.|pdf=|usr=020}}
| |
| − | {{tp|p=33121250|t=2020. The COVID-19 Pandemic and the Relevance of Ayurveda's Whole Systems Approach to Health and Disease Management.|pdf=|usr=020}}
| |
| − | {{tp|p=33064060|t=2020. Magnesium and COVID-19 - Some Further Comments - A Commentary on Wallace TC. Combating COVID-19 and Building Immune Resilience: A Potential Role for Magnesium Nutrition? J Am Coll Nutr. 2020;1-9. doi:10.1080/07315724.2020.1785971. Cited in: PMID: 32649272.|pdf=|usr=020}}
| |
| − | {{tp|p=33048028|t=2020. Does Serum Vitamin D Level Affect COVID-19 Infection and Its Severity?-A Case-Control Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33136164|t=2020. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.|pdf=|usr=020}}
| |
| − | {{tp|p=33087532|t=2020. Upcoming SARS-CoV-2 vaccine: expectations and reality.|pdf=|usr=020}}
| |
| − |
| |
| − | {{tp|p=33072869|t=2020. Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality.|pdf=|usr=020}}
| |
| − | {{tp|p=33052316|t=2020. Use of oral antiseptics for SARS-CoV-2 infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33038588|t=2020. COVID-19 induced ARDS, and the use of galantamine to activate the cholinergic anti-inflammatory pathway.|pdf=|usr=020}}
| |
| − | {{tp|p=33045596|t=2020. A possible application of hinokitiol as a natural zinc ionophore and anti-infective agent for the prevention and treatment of COVID-19 and viral infections.|pdf=|usr=020}}
| |
| − | {{tp|p=33129578|t=2020. May interferon lambda be a novel therapeutic approach against COVID-19?|pdf=|usr=020}}
| |
| − | {{tp|p=33129007|t=2020. Therapeutic potential for clomiphene, a selective estrogen receptor modulator, in the treatment of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33129009|t=2020. Ac2-26 mimetic peptide of annexin A1 to treat severe COVID-19: A hypothesis.|pdf=|usr=020}}
| |
| − | {{tp|p=33129008|t=2020. A multiple therapy hypothesis for treatment of COVID-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33029105|t=2020. Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment by QTY Code-Designed Detergent-Free Chemokine Receptors.|pdf=|usr=020}}
| |
| − | {{tp|p=33048786|t=2020. Efectos adversos de lopinavir/ritonavir en enfermedad grave por coronavirus (COVID-19).|pdf=|usr=020}}
| |
| − | {{tp|p=33048783|t=2020. Terapia con plasma de convalecientes en pacientes COVID-19 en la Provincia de Buenos Aires.|pdf=|usr=020}}
| |
| − | {{tp|p=33194150|t=2020. "Hemolysis, or not Hemolysis, that is the Question". Use of Hydroxychloroquine in a Patient with COVID-19 Infection and G6PD Deficiency.|pdf=|usr=020}}
| |
| − | {{tp|p=33196010|t=2020. Potential Role of Anti-Complement Agents in the Treatment of COVID-19-Related ARDS.|pdf=|usr=020}}
| |
| − | {{tp|p=33196003|t=2020. Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARSCoV-2): What is the Evidence?|pdf=|usr=020}}
| |
| − | {{tp|p=33091582|t=2020. Inhibition of N-linked Glycosylation by Tunicamycin May Contribute to The Treatment of SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33092045|t=2020. Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico.|pdf=|usr=020}}
| |
| − | {{tp|p=33080900|t=2020. In silico Investigation on the Inhibiting Role of Nicotine/Caffeine by Blocking the S Protein of SARS-CoV-2 Versus ACE2 Receptor.|pdf=|usr=020}}
| |
| − | {{tp|p=33172191|t=2020. New Technologies for Influenza Vaccines.|pdf=|usr=020}}
| |
| − | {{tp|p=33167389|t=2020. Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases.|pdf=|usr=020}}
| |
| − | {{tp|p=33064288|t=2020. SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions.|pdf=|usr=020}}
| |
| − | {{tp|p=33079314|t=2020. Using Chou's 5-steps rule to study pharmacophore-based virtual screening of SARS-CoV-2 Mpro inhibitors.|pdf=|usr=020}}
| |
| − | {{tp|p=33065038|t=2020. Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines.|pdf=|usr=020}}
| |
| − | {{tp|p=32911757|t=2020. Polyphenols vs. Coronaviruses: How Far Has Research Moved Forward?|pdf=|usr=020}}
| |
| − | {{tp|p=33137605|t=2020. Can dexamethasone prevent the seizures induced by SARS-CoV-2 infection?|pdf=|usr=020}}
| |
| − | {{tp|p=33087898|t=2020. COVID-19 antibodies on trial.|pdf=|usr=020}}
| |
| − | {{tp|p=33028832|t=2020. Many small steps towards a COVID-19 drug.|pdf=|usr=020}}
| |
| − | {{tp|p=33087721|t=2020. Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein.|pdf=|usr=020}}
| |
| − | {{tp|p=33082342|t=2020. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics.|pdf=|usr=020}}
| |
| − | {{tp|p=33149112|t=2020. Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33188207|t=2020. Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys.|pdf=|usr=020}}
| |
| − | {{tp|p=33090359|t=2020. Hordatines as a Potential Inhibitor of COVID-19 Main Protease and RNA Polymerase: An In-Silico Approach.|pdf=|usr=020}}
| |
| − | {{tp|p=33057955|t=2020. The upshot of Polyphenolic compounds on immunity amid COVID-19 pandemic and other emerging communicable diseases: An appraisal.|pdf=|usr=020}}
| |
| − | {{tp|p=33067570|t=2020. Learning from the past: development of safe and effective COVID-19 vaccines.|pdf=|usr=020}}
| |
| − | {{tp|p=33082565|t=2020. HCQ use not protective against SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33030660|t=2020. QTc interval prolongation, COVID-19 and chloroquine.|pdf=|usr=020}}
| |
| − | {{tp|p=33042552|t=2020. Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review.|pdf=|usr=020}}
| |
| − | {{tp|p=32983541|t=2020. First evaluation of hydroxychloroquine recommendations in treating SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33106729|t=2020. A potential treatment for COVID-19 based on modal characteristics and dynamic responses analysis of 2019-nCoV.|pdf=|usr=020}}
| |
| − | {{tp|p=33083549|t=2020. The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33088593|t=2020. Rabies virus-based COVID-19 vaccine CORAVAX induces high levels of neutralizing antibodies against SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33083031|t=2020. Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein.|pdf=|usr=020}}
| |
| − | {{tp|p=33083026|t=2020. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses.|pdf=|usr=020}}
| |
| − | {{tp|p=33134417|t=2020. Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33117850|t=2020. Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience.|pdf=|usr=020}}
| |
| − | {{tp|p=33072814|t=2020. Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia.|pdf=|usr=020}}
| |
| − | {{tp|p=33085486|t=2020. Cyanoamidine Cyclization Approach to Remdesivir's Nucleobase.|pdf=|usr=020}}
| |
| − | {{tp|p=33048168|t=2020. Sex-specific association between vitamin D deficiency and COVID-19 mortality in older patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33073552|t=2020. Repurposing of drugs for Covid-19: a systematic review and meta-analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33089038|t=2020. Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia.|pdf=|usr=020}}
| |
| − | {{tp|p=33076482|t=2020. Sepsis, Phages, and COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33050463|t=2020. Genomic Diversity and Hotspot Mutations in 30,983 SARS-CoV-2 Genomes: Moving Toward a Universal Vaccine for the "Confined Virus"?|pdf=|usr=020}}
| |
| − | {{tp|p=33167401|t=2020. Antibody-Based Immunotherapeutic Strategies for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33182546|t=2020. SARS-CoV-2 Vaccines: Inactivation by Gamma Irradiation for T and B Cell Immunity.|pdf=|usr=020}}
| |
| − | {{tp|p=33194450|t=2020. The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review.|pdf=|usr=020}}
| |
| − | {{tp|p=33080877|t=2020. Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33182811|t=2020. Role of 2-[(18)F]FDG as a Radiopharmaceutical for PET/CT in Patients with COVID-19: A Systematic Review.|pdf=|usr=020}}
| |
| − | {{tp|p=33105618|t=2020. Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing.|pdf=|usr=020}}
| |
| − | {{tp|p=33165762|t=2020. The effect of tocilizumab on cytokine release syndrome in COVID-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33113146|t=2020. Overview of the possible role of vitamin C in management of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33108587|t=2020. Favipiravir use for SARS CoV-2 infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33063271|t=2020. Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33040252|t=2020. Observational study of people infected with SARS-Cov-2, treated with amantadine.|pdf=|usr=020}}
| |
| − | {{tp|p=33096221|t=2020. Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro.|pdf=|usr=020}}
| |
| − | {{tp|p=33124786|t=2020. Nucleotide analogues as inhibitors of SARS-CoV Polymerase.|pdf=|usr=020}}
| |
| − | {{tp|p=33158717|t=2020. Shufeng Jiedu, a promising herbal therapy for moderate COVID-19:Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study.|pdf=|usr=020}}
| |
| − | {{tp|p=33041173|t=2020. Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33067112|t=2020. Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33000510|t=2020. Molecular and functional resemblance of dexamethasone and quercetin: A paradigm worth exploring in dexamethasone-nonresponsive COVID-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=32969524|t=2020. The natural way forward: Molecular dynamics simulation analysis of phytochemicals from Indian medicinal plants as potential inhibitors of SARS-CoV-2 targets.|pdf=|usr=020}}
| |
| − | {{tp|p=32945590|t=2020. Bee products as a source of promising therapeutic and chemoprophylaxis strategies against COVID-19 (SARS-CoV-2).|pdf=|usr=020}}
| |
| − | {{tp|p=33037564|t=2020. Potential Inhibitors for SARS-CoV-2 and Functional Food Components as Nutritional Supplement for COVID-19: A Review.|pdf=|usr=020}}
| |
| − | {{tp|p=33173705|t=2020. The Race for a COVID-19 Vaccine: Current Trials, Novel Technologies, and Future Directions.|pdf=|usr=020}}
| |
| − | {{tp|p=33166303|t=2020. Monitor for COVID-19 vaccine resistance evolution during clinical trials.|pdf=|usr=020}}
| |
| − | {{tp|p=33180803|t=2020. Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking.|pdf=|usr=020}}
| |
| − | {{tp|p=33175880|t=2020. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33173052|t=2020. Lung transcriptome of a COVID-19 patient and systems biology predictions suggest impaired surfactant production which may be druggable by surfactant therapy.|pdf=|usr=020}}
| |
| − | {{tp|p=33127296|t=2020. Transforming vaccine development.|pdf=|usr=020}}
| |
| − | {{tp|p=33159214|t=2020. Shelter from the cytokine storm: pitfalls and prospects in the development of SARS-CoV-2 vaccines for an elderly population.|pdf=|usr=020}}
| |
| − | {{tp|p=33169564|t=2020. [Mesenchymal stem cells in therapy of coronavirus disease 2019 - a review].|pdf=|usr=020}}
| |
| − | {{tp|p=33169563|t=2020. [Mesenchymal stem cells in the treatment of COVID-19-progress and challenges].|pdf=|usr=020}}
| |
| − | {{tp|p=32951007|t=2020. Targeting multiple epitopes on the spike protein: a new hope for COVID-19 antibody therapy.|pdf=|usr=020}}
| |
| − | {{tp|p=33043784|t=2020. High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33107685|t=2020. Severe Acute Respiratory Syndrome Coronavirus-2 Spike Protein Nanogel as a Pro-Antigen Strategy with Enhanced Protective Immune Responses.|pdf=|usr=020}}
| |
| − | {{tp|p=33163859|t=2020. Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review.|pdf=|usr=020}}
| |
| − | {{tp|p=33134845|t=2020. Antidiabetes Agents against Sars-Cov-2 Infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33043249|t=2020. Reactivation of SARS-CoV-2 after Asymptomatic Infection while on High-Dose Corticosteroids. Case Report.|pdf=|usr=020}}
| |
| − | {{tp|p=33103063|t=2020. Corticosteroids in COVID-19: Is it Rational? A Systematic Review and Meta-Analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33103062|t=2020. Coinfection of Tuberculosis Pneumonia and COVID-19 in a Patient Vaccinated with Bacille Calmette-Guerin (BCG): Case Report.|pdf=|usr=020}}
| |
| − | {{tp|p=33062267|t=2020. Convalescent plasma appears efficacious and safe in COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33177829|t=2020. N-Acetylcysteine to Combat COVID-19: An Evidence Review.|pdf=|usr=020}}
| |
| − | {{tp|p=33111176|t=2020. Patient Contribution to the Development and Safe Use of Medicines During the Covid-19 Pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33172237|t=2020. Vitamin D og covid-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33052306|t=2020. Comparative docking studies to understand the binding affinity of nicotine with soluble ACE2 (sACE2)-SARS-CoV-2 complex over sACE2.|pdf=|usr=020}}
| |
| − | {{tp|p=33169107|t=2020. Synergy of melanin and vitamin-D may play a fundamental role in preventing SARS-CoV-2 infections and halt COVID-19 by inactivating furin protease.|pdf=|usr=020}}
| |
| − | {{tp|p=33072871|t=2020. Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the Midwest.|pdf=|usr=020}}
| |
| − | {{tp|p=33153922|t=2020. Repurposing Antimalarials to Tackle the COVID-19 Pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33153921|t=2020. Potential Influence of Helminth Molecules on COVID-19 Pathology.|pdf=|usr=020}}
| |
| − | {{tp|p=33027867|t=2020. COVID-19 death and BCG vaccination.|pdf=|usr=020}}
| |
| − | {{tp|p=33169711|t=2020. The role of probiotics in COVID-19 treatment: Gut microbiota can help physicians in the outbreak.|pdf=|usr=020}}
| |
| − | {{tp|p=33078604|t=2020. A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma.|pdf=|usr=020}}
| |
| − | {{tp|p=33177924|t=2020. The Effect of Therapeutic Plasma Exchange on COVID-19 Therapy.|pdf=|usr=020}}
| |
| − | {{tp|p=33052520|t=2020. Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit.|pdf=|usr=020}}
| |
| − | {{tp|p=33130382|t=2021. A natural food preservative peptide nisin can interact with the SARS-CoV-2 spike protein receptor human ACE2.|pdf=|usr=020}}
| |
| − | {{tp|p=33115670|t=2021. Ozone therapy in COVID-19: A narrative review.|pdf=|usr=020}}
| |
| − | {{tp|p=33086123|t=2021. Nitric oxide (NO) and nanoparticles - Potential small tools for the war against COVID-19 and other human coronavirus infections.|pdf=|usr=020}}
| |
| − | {{tp|p=33039544|t=2021. Anti-inflammatory drugs and the renin-angiotensin-aldosterone system: Current knowledge and potential effects on early SARS-CoV-2 infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33080984|t=2020. Identification and Tracking of Antiviral Drug Combinations.|pdf=|usr=020}}
| |
| − | {{tp|p=33081350|t=2020. Viral Related Tools against SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33072240|t=2020. Enhancing innate immunity against virus in times of COVID-19: Trying to untangle facts from fictions.|pdf=|usr=020}}
| |
| − | {{tp|p=33083387|t=2020. Role of monoclonal antibody drugs in the treatment of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33033561|t=2020. Perspectives on mesenchymal stem/progenitor cells and their derivates as potential therapies for lung damage caused by COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33178392|t=2020. Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome.|pdf=|usr=020}}
| |
| − |
| |
| − | {{tp|p=33138964|t=2020. Inhaled nitric oxide minimally improves oxygenation in COVID-19 related acute respiratory distress syndrome.|pdf=|usr=020}}
| |
| − | {{tp|p=33133323|t=2020. A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33136431|t=2020. COVID-19 Basics and Vaccine Development with a Canadian Perspective.|pdf=|usr=020}}
| |
| − | {{tp|p=33129484|t=2020. The importance of robust research methodology in the era of COVID-19 and beyond.|pdf=|usr=020}}
| |
| − | {{tp|p=33043132|t=2020. Adjunct low level laser therapy (LLLT) in a morbidly obese patient with severe COVID-19 pneumonia: A case report.|pdf=|usr=020}}
| |
| − | {{tp|p=33082891|t=2020. The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33058086|t=2020. Safety and Effectiveness of Hydroxychloroquine and Azithromycin Combination Therapy for Treatment of Hospitalized Patients with COVID-19: A Propensity-Matched Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33083006|t=2020. Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1 phosphorylation.|pdf=|usr=020}}
| |
| − | {{tp|p=33152278|t=2020. Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics.|pdf=|usr=020}}
| |
| − | {{tp|p=33137649|t=2020. Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33040594|t=2020. Stem Cell Transplantation Therapy: A Potential Method for Treating Cytokine Storm Syndromes Induced by COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33160536|t=2020. First, Do No Harm: Caution Against Use of Tocilizumab in COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33030653|t=2020. Clinical Practice Guidelines and Experts' Consensuses for Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Chinese Herbal Medicine: A Systematic Review.|pdf=|usr=020}}
| |
| − | {{tp|p=33133232|t=2020. Anti-COVID-19 drug screening: Frontier concepts and core technologies.|pdf=|usr=020}}
| |
| − | {{tp|p=33073222|t=2020. Rapid Response to Cytokine Storm Inhibition using Anakinra in a Patient with COVID-19 Myocarditis.|pdf=|usr=020}}
| |
| − | {{tp|p=33042544|t=2020. Severe coronavirus disease 2019 (COVID-19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series.|pdf=|usr=020}}
| |
| − | {{tp|p=33116907|t=2020. Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19?|pdf=|usr=020}}
| |
| − | {{tp|p=33163696|t=2020. Is BCG associated with reduced incidence of COVID-19? A meta-regression of global data from 160 countries.|pdf=|usr=020}}
| |
| − | {{tp|p=33102933|t=2020. Is the shielding effect of cholecalciferol in SARS CoV-2 infection dependable? An evidence based unraveling.|pdf=|usr=020}}
| |
| − | {{tp|p=32935331|t=2020. Vaccines for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33128197|t=2020. Emerging treatment strategies for COVID-19 infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33065237|t=2020. Outcome of hospitalized patients with COVID-19 pneumonia treated with high-dose immunoglobulin therapy in a prospective case series.|pdf=|usr=020}}
| |
| − | {{tp|p=33166647|t=2020. Re: effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: author's response.|pdf=|usr=020}}
| |
| − | {{tp|p=33161150|t=2020. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33055231|t=2020. Remdesivir against COVID-19 and Other Viral Diseases.|pdf=|usr=020}}
| |
| − | {{tp|p=33033459|t=2020. A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime?|pdf=|usr=020}}
| |
| − | {{tp|p=33097304|t=2020. Polydatin and its potential protective effect on COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33162193|t=2020. Reply - Letter to the editor - Nutritional interventions to modulate haemoglobin-oxygen affinity in COVID-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33168324|t=2020. Nutritional interventions to modulate haemoglobin-oxygen affinity in COVID-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33088506|t=2020. Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19).|pdf=|usr=020}}
| |
| − | {{tp|p=33082954|t=2020. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study.|pdf=|usr=020}}
| |
| − | {{tp|p=33135358|t=2020. Immunological strategies against spike protein: Neutralizing antibodies and vaccine development for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33135340|t=2020. Instantaneous "catch-and-kill" inactivation of SARS-CoV-2 by nitride ceramics.|pdf=|usr=020}}
| |
| − | {{tp|p=33144317|t=2020. Key populations for early COVID-19 immunization: preliminary guidance for policy.|pdf=|usr=020}}
| |
| − | {{tp|p=33174415|t=2020. Interactive Molecular Dynamics in Virtual Reality Is an Effective Tool for Flexible Substrate and Inhibitor Docking to the SARS-CoV-2 Main Protease.|pdf=|usr=020}}
| |
| − | {{tp|p=33175236|t=2020. Molecular basis for drug repurposing to study the interface of the S protein in SARS-CoV-2 and human ACE2 through docking, characterization, and molecular dynamics for natural drug candidates.|pdf=|usr=020}}
| |
| − | {{tp|p=33174418|t=2020. Epitope-Based Potential Vaccine Candidate for Humoral and Cell-Mediated Immunity to Combat Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33147968|t=2020. In Silico Antibody Mutagenesis for Optimizing Its Binding to Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2.|pdf=|usr=020}}
| |
| − | {{tp|p=33173161|t=2020. Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia.|pdf=|usr=020}}
| |
| − | {{tp|p=33063409|t=2020. Treatment of Stage 3 COVID-19 With Transcutaneous Auricular Vagus Nerve Stimulation Drastically Reduces Interleukin-6 Blood Levels: A Report on Two Cases.|pdf=|usr=020}}
| |
| − | {{tp|p=33158787|t=2020. Rationale and evidence on the use of tocilizumab in COVID-19: A systematic review. Authors' reply.|pdf=|usr=020}}
| |
| − | {{tp|p=33158786|t=2020. Interleukin-6 blockade with tocilizumab in COVID-19: Does it live up to its hype?|pdf=|usr=020}}
| |
| − | {{tp|p=33151329|t=2020. Hydrogen therapy as an effective and novel adjuvant treatment against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33151328|t=2020. Response to: Hydrogen therapy as an effective and novel adjuvant treatment against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33047045|t=2020. Targeting the glycan of receptor binding domain with jacalin as a novel approach to develop a treatment against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33065184|t=2020. Low dose radiation therapy for COVID-19: Effective dose and estimation of cancer risk.|pdf=|usr=020}}
| |
| − | {{tp|p=33126054|t=2020. Prediction of survival odds in COVID-19 by zinc, age and selenoprotein P as composite biomarker.|pdf=|usr=020}}
| |
| − | {{tp|p=33043232|t=2020. Thrombo-inflammation response to Tocilizumab in COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33067149|t=2020. Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series.|pdf=|usr=020}}
| |
| − | {{tp|p=33190086|t=2020. Efficacy of therapeutic plasma exchange in the treatment of penn class 3 and 4 cytokine release syndrome complicating COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33041391|t=2020. Coronaviruses and Nature's Pharmacy for the Relief of Coronavirus Disease 2019.|pdf=|usr=020}}
| |
| − | {{tp|p=33053024|t=2020. Sindrome do desconforto respiratorio agudo associada a COVID-19 tratada com DEXametasona (CoDEX): delineamento e justificativa de um estudo randomizado.|pdf=|usr=020}}
| |
| − | {{tp|p=33070542|t=2020. Current targets and drug candidates for prevention and treatment of SARS-CoV-2 (COVID-19) infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33070539|t=2020. Vitamin D deficiency in association with endothelial dysfunction: Implications for patients with COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33077410|t=2020. Usefulness and safety of self-electrocardiographic monitoring during treatment with hydroxychloroquine and azithromycin in COVID-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33069612|t=2020. Main challenges of electrolyte imbalance in older patients with coronavirus disease and risk of QT prolongation. Response.|pdf=|usr=020}}
| |
| − | {{tp|p=33120400|t=2020. Infusion of Convalescent Plasma is associated with Clinical Improvement in Critically Ill Patients With Covid-19: A Comment.|pdf=|usr=020}}
| |
| − | {{tp|p=33077267|t=2020. Chez les sujets hospitalises pour COVID-19, est-ce que la dexamethasone diminue la mortalite a 28jours comparativement au traitement standard ?|pdf=|usr=020}}
| |
| − | {{tp|p=33087414|t=2020. Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline.|pdf=|usr=020}}
| |
| − | {{tp|p=33100032|t=2020. Exploring RdRp-remdesivir interactions to screen RdRp inhibitors for the management of novel coronavirus 2019-nCoV.|pdf=|usr=020}}
| |
| − | {{tp|p=33110386|t=2020. Computational selection of flavonoid compounds as inhibitors against SARS-CoV-2 main protease, RNA-dependent RNA polymerase and spike proteins: A molecular docking study.|pdf=|usr=020}}
| |
| − | {{tp|p=33067239|t=2020. Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design.|pdf=|usr=020}}
| |
| − | {{tp|p=33158912|t=2020. Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against M(pro) and cathepsin L.|pdf=|usr=020}}
| |
| − | {{tp|p=33187978|t=2020. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.|pdf=|usr=020}}
| |
| − | {{tp|p=33097472|t=2020. Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response.|pdf=|usr=020}}
| |
| − | {{tp|p=33036961|t=2020. Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals.|pdf=|usr=020}}
| |
| − | {{tp|p=33163740|t=2020. Coronavirus Disease (COVID-19) and Africa: acclaimed home remedies.|pdf=|usr=020}}
| |
| − | {{tp|p=33097791|t=2020. A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone.|pdf=|usr=020}}
| |
| − | {{tp|p=33082473|t=2020. Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33077899|t=2020. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana.|pdf=|usr=020}}
| |
| − | {{tp|p=33077836|t=2020. Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2.|pdf=|usr=020}}
| |
| − | {{tp|p=33077821|t=2020. Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation.|pdf=|usr=020}}
| |
| − | {{tp|p=33138949|t=2020. Letter to the editor: Covid-19 and Vit-D: Disease mortality negatively correlates with sunlight exposure.|pdf=|usr=020}}
| |
| − | {{tp|p=33129692|t=2020. CGRP Receptor Antagonism in COVID-19: Potential Cardiopulmonary Adverse Effects.|pdf=|usr=020}}
| |
| − | {{tp|p=33121422|t=2020. Efficacy of Lopinavir/Ritonavir Compared With Standard Care for Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review.|pdf=|usr=020}}
| |
| − | {{tp|p=33069201|t=2020. BCG vaccine, a ray of hope in treating Severe Acute Respiratory Syndrome (SARS).|pdf=|usr=020}}
| |
| − | {{tp|p=33050869|t=2020. COVID-19 And Type 2 Diabetes Mellitus: Hydroxychloroquine May Be The Holy Grail.|pdf=|usr=020}}
| |
| − | {{tp|p=33118690|t=2020. Prophylactic and therapeutic topical povidone-iodine in coronavirus disease 2019 (COVID-19): What is the evidence?|pdf=|usr=020}}
| |
| − | {{tp|p=33063627|t=2020. ECCO2R with cytokine filtering in COVID-19 patients: Who wants to go down this road?|pdf=|usr=020}}
| |
| − | {{tp|p=33141018|t=2020. COVID-19: Cytokine storm modulation/blockade with oral polyvalent immunoglobulins (PVIG, KMP01D): A potential and safe therapeutic agent (Primum nil nocere).|pdf=|usr=020}}
| |
| − | {{tp|p=33156564|t=2020. An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine.|pdf=|usr=020}}
| |
| − | {{tp|p=33090785|t=2020. Virtual Double-System Single-Box: A Nonequilibrium Alchemical Technique for Absolute Binding Free Energy Calculations: Application to Ligands of the SARS-CoV-2 Main Protease.|pdf=|usr=020}}
| |
| − | {{tp|p=33159440|t=2020. Vitamin D Status in Hospitalized Patients with SARS-CoV-2 Infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33128482|t=2020. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33098139|t=2020. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.|pdf=|usr=020}}
| |
| − | {{tp|p=33180360|t=2020. Treatment With Tocilizumab for Patients With COVID-19 Infections: A Case-Series Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33118617|t=2020. Effect of remdesivir on mortality in patients with COVID-19: A meta-analysis of randomized control trials.|pdf=|usr=020}}
| |
| − | {{tp|p=33155686|t=2020. Defining IL-6 levels in healthy individuals: A meta-analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33150961|t=2020. SARS-CoV-2 and inflammatory responses: from mechanisms to the potential therapeutic use of intravenous immunoglobulin.|pdf=|usr=020}}
| |
| − | {{tp|p=33164959|t=2020. Navigating the ethical Scylla and Charybdis of the COVID vaccine.|pdf=|usr=020}}
| |
| − | {{tp|p=33180938|t=2020. Update from the Advisory Committee on Immunization Practices.|pdf=|usr=020}}
| |
| − | {{tp|p=33115235|t=2020. Hydroxychloroquine Exhibits a Strong Complex Interaction with DNA: Unraveling the Mechanism of Action.|pdf=|usr=020}}
| |
| − | {{tp|p=33108677|t=2020. Melatonin controversies, an update.|pdf=|usr=020}}
| |
| − | {{tp|p=33042589|t=2020. Pharmacological approaches to the treatment of COVID-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33073873|t=2020. Can Low-Intensity Pulsed Ultrasound Treat Discrete Pulmonary Lesions in Patients With COVID-19?|pdf=|usr=020}}
| |
| − | {{tp|p=33080017|t=2020. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.|pdf=|usr=020}}
| |
| − | {{tp|p=33080005|t=2020. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.|pdf=|usr=020}}
| |
| − | {{tp|p=33080002|t=2020. Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33079980|t=2020. Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia.|pdf=|usr=020}}
| |
| − | {{tp|p=33094848|t=2020. Clinical Nutrition Research and the COVID-19 Pandemic: A Scoping Review of the ASPEN COVID-19 Task Force on Nutrition Research.|pdf=|usr=020}}
| |
| − | {{tp|p=33131470|t=2020. [Proactive anti-inflammatory and anticoagulant therapy in the treatment of advanced stages of novel coronavirus infection (COVID-19). Case Series and Study Design: COLchicine versus ruxolitinib and secukinumab in open prospective randomIzed trial (COLORIT)].|pdf=|usr=020}}
| |
| − | {{tp|p=33125934|t=2020. Who should be prioritised for COVID-19 vaccines?|pdf=|usr=020}}
| |
| − | {{tp|p=33125914|t=2020. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33035967|t=2020. COVID-19, myocardial edema and dexamethasone.|pdf=|usr=020}}
| |
| − | {{tp|p=33151866|t=2020. COVID-19 et vaccination : une deregulation globale.|pdf=|usr=020}}
| |
| − | {{tp|p=33080270|t=2020. Mediterranean diet as a nutritional approach for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33109047|t=2020. Perspectives for the use of N-acetylcysteine as a candidate drug to treat COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33169027|t=2020. What Pfizer's landmark COVID vaccine results mean for the pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33177689|t=2020. Russia announces positive COVID-vaccine results from controversial trial.|pdf=|usr=020}}
| |
| − | {{tp|p=33168970|t=2020. COVID vaccination logistics: five steps to take now.|pdf=|usr=020}}
| |
| − | {{tp|p=33084621|t=2020. Bromelain: A Review on its Potential as a Therapy for the Management of Covid-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33039952|t=2020. Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19).|pdf=|usr=020}}
| |
| − |
| |
| − | {{tp|p=33085408|t=2020. Remdesivir|pdf=|usr=020}}
| |
| − | {{tp|p=33088671|t=2020. Targeting complement cascade: an alternative strategy for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33140033|t=2020. Targeting the SARS-CoV-2 RNA Genome with Small Molecule Binders and Ribonuclease Targeting Chimera (RIBOTAC) Degraders.|pdf=|usr=020}}
| |
| − | {{tp|p=33140032|t=2020. Fighting COVID-19 Using Molecular Dynamics Simulations.|pdf=|usr=020}}
| |
| − | {{tp|p=33140031|t=2020. New Chemical Modalities Enabling Specific RNA Targeting and Degradation: Application to SARS-CoV-2 RNA.|pdf=|usr=020}}
| |
| − | {{tp|p=33072646|t=2020. Necessity to Prioritize Research Activities for a Better Public Health Response to Coronavirus Disease-2019 Pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=32864330|t=2020. The effects of Sambucus nigra berry on acute respiratory viral infections: A rapid review of clinical studies.|pdf=|usr=020}}
| |
| − | {{tp|p=32837900|t=2020. The effects of Hedera helix on viral respiratory infections in humans: A rapid review.|pdf=|usr=020}}
| |
| − | {{tp|p=33062600|t=2020. Angiotensin 1-7: A Novel Strategy in COVID-19 Treatment.|pdf=|usr=020}}
| |
| − | {{tp|p=33173718|t=2020. Bioinspired DNase-I-Coated Melanin-Like Nanospheres for Modulation of Infection-Associated NETosis Dysregulation.|pdf=|usr=020}}
| |
| − | {{tp|p=33173846|t=2020. Adaptive Evolution of Peptide Inhibitors for Mutating SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33108622|t=2020. Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33043128|t=2020. A Cyclodextrin-Stabilized Spermine-Tagged Drug Triplex that Targets Theophylline to the Lungs Selectively in Respiratory Emergency.|pdf=|usr=020}}
| |
| − | {{tp|p=33173808|t=2020. Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector.|pdf=|usr=020}}
| |
| − | {{tp|p=33173809|t=2020. Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus.|pdf=|usr=020}}
| |
| − | {{tp|p=33034016|t=2020. Prognostic role of nutritional status in elderly patients hospitalized for COVID-19: a monocentric study.|pdf=|usr=020}}
| |
| − | {{tp|p=33044799|t=2020. Pandemic and promise: progress towards finding an effective treatment for Novel Coronavirus 19.|pdf=|usr=020}}
| |
| − | {{tp|p=33029761|t=2020. Metal Nanoparticles: a Promising Treatment for Viral and Arboviral Infections.|pdf=|usr=020}}
| |
| − | {{tp|p=33094446|t=2020. Zinc and COVID-19: Basis of Current Clinical Trials.|pdf=|usr=020}}
| |
| − | {{tp|p=33170448|t=2020. Trace Element Zinc, a Nature's Gift to Fight Unprecedented Global Pandemic COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33078028|t=2020. Is a healthy microbiome responsible for lower mortality in COVID-19?|pdf=|usr=020}}
| |
| − | {{tp|p=33116397|t=2020. Glycopeptides as Potential Interventions for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33130319|t=2020. Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm.|pdf=|usr=020}}
| |
| − | {{tp|p=33152914|t=2020. CRISPR/Cas13: A potential therapeutic option of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33113418|t=2020. Potential of natural astaxanthin in alleviating the risk of cytokine storm in COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33049583|t=2020. GB-2 inhibits ACE2 and TMPRSS2 expression: In vivo and in vitro studies.|pdf=|usr=020}}
| |
| − | {{tp|p=33102585|t=2020. Phytochemicals from Selective Plants Have Promising Potential against SARS-CoV-2: Investigation and Corroboration through Molecular Docking, MD Simulations, and Quantum Computations.|pdf=|usr=020}}
| |
| − | {{tp|p=33029513|t=2020. Alkaloids from Cryptolepis sanguinolenta as Potential Inhibitors of SARS-CoV-2 Viral Proteins: An In Silico Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33029499|t=2020. Convalescent Plasma: A Challenging Tool to Treat COVID-19 Patients-A Lesson from the Past and New Perspectives.|pdf=|usr=020}}
| |
| − | {{tp|p=33152192|t=2020. [Cloroquina y sus derivados en el manejo de la COVID-19: una revision sistematica exploratoria].|pdf=|usr=020}}
| |
| − | {{tp|p=33066343|t=2020. A Possible Path towards Rapid Development of Live-Attenuated SARS-CoV-2 Vaccines: Plunging into the Natural Pool.|pdf=|usr=020}}
| |
| − | {{tp|p=33172012|t=2020. Fragment Library of Natural Products and Compound Databases for Drug Discovery.|pdf=|usr=020}}
| |
| − | {{tp|p=33091672|t=2020. Nano-sized formazan analogues: Synthesis, structure elucidation, antimicrobial activity and docking study for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33160024|t=2020. Discovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33135430|t=2020. CRISPR vs COVID-19: how can gene editing help beat a virus?|pdf=|usr=020}}
| |
| − | {{tp|p=33087047|t=2020. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial.|pdf=|usr=020}}
| |
| − | {{tp|p=32933914|t=2020. Cytokine storm and use of anakinra in a patient with COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33087452|t=2020. Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK?|pdf=|usr=020}}
| |
| − | {{tp|p=33122319|t=2020. Timely access to trial data in the context of a pandemic: the time is now.|pdf=|usr=020}}
| |
| − | {{tp|p=33158571|t=2020. Methylene blue as an anti-COVID-19 mouthwash in dental practice.|pdf=|usr=020}}
| |
| − | {{tp|p=33111169|t=2020. No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33143316|t=2020. Aprotinin Inhibits SARS-CoV-2 Replication.|pdf=|usr=020}}
| |
| − | {{tp|p=33105869|t=2020. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.|pdf=|usr=020}}
| |
| − | {{tp|p=33129791|t=2020. "Impact of Corticosteroids in COVID-19 Outcomes: Systematic Review and Meta-Analysis".|pdf=|usr=020}}
| |
| − | {{tp|p=33075378|t=2020. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.|pdf=|usr=020}}
| |
| − | {{tp|p=33065103|t=2020. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The ICON Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33127564|t=2020. Commentary on "Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy" by D.C. Mastellos et al.|pdf=|usr=020}}
| |
| − | {{tp|p=33115645|t=2020. Response to "Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19".|pdf=|usr=020}}
| |
| − | {{tp|p=33117530|t=2020. Cilastatin: a potential treatment strategy against COVID-19 that may decrease viral replication and protect from the cytokine storm.|pdf=|usr=020}}
| |
| − | {{tp|p=33098998|t=2020. Rational for meta-analysis and randomized treatment: the COVID-19 example.|pdf=|usr=020}}
| |
| − | {{tp|p=33096242|t=2020. Has the door closed on hydroxychloroquine for SARS-COV-2?|pdf=|usr=020}}
| |
| − | {{tp|p=33068758|t=2020. Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine.|pdf=|usr=020}}
| |
| − | {{tp|p=33094324|t=2020. Exploring lectin-glycan interactions to combat COVID-19: lessons acquired from other enveloped viruses.|pdf=|usr=020}}
| |
| − | {{tp|p=33181328|t=2020. Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia.|pdf=|usr=020}}
| |
| − | {{tp|p=33047152|t=2020. Vaccine development in the SARS-CoV-2 pandemic: a balancing act on accuracy and speed.|pdf=|usr=020}}
| |
| − | {{tp|p=33179911|t=2020. Quercetin and Its Metabolites Inhibit Recombinant Human Angiotensin-Converting Enzyme 2 (ACE2) Activity.|pdf=|usr=020}}
| |
| − | {{tp|p=33031488|t=2020. Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33089306|t=2020. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authors' response.|pdf=|usr=020}}
| |
| − | {{tp|p=33063117|t=2020. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33161818|t=2020. The Circadian Clock and Viral Infections.|pdf=|usr=020}}
| |
| − | {{tp|p=33118480|t=2020. Uncaria tomentosa (cat's claw): a promising herbal medicine against SARS-CoV-2/ACE-2 junction and SARS-CoV-2 spike protein based on molecular modeling.|pdf=|usr=020}}
| |
| − | {{tp|p=33164664|t=2020. Multi-epitope vaccine against SARS-CoV-2 applying immunoinformatics and molecular dynamics simulation approaches.|pdf=|usr=020}}
| |
| − | {{tp|p=33181454|t=2020. The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019.|pdf=|usr=020}}
| |
| − | {{tp|p=33058394|t=2020. SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies.|pdf=|usr=020}}
| |
| − | {{tp|p=33176176|t=2020. Early, low-dose, short-term methylprednisolone decreased the mortality in critical COVID-19 patients: A multicenter retrospective cohort study.|pdf=|usr=020}}
| |
| − | {{tp|p=33104179|t=2020. Neutralizing Antibody Responses in COVID-19 Convalescent Sera.|pdf=|usr=020}}
| |
| − | {{tp|p=33153629|t=2020. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33113295|t=2020. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33085857|t=2020. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33067219|t=2020. Morphoproteomics Identifies the Vitamin D Receptor as a Potential Therapeutic Partner in Alveolar Pneumocytes for COVID-19 Infected Patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33075259|t=2020. In adults exposed to COVID-19, hydroxychloroquine did not reduce confirmed or probable COVID-19; trial stopped for futility.|pdf=|usr=020}}
| |
| − | {{tp|p=33095083|t=2021. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019.|pdf=|usr=020}}
| |
| − | {{tp|p=33127663|t=2020. Response to 'Neither earlier not late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study' by Moiseev et al.|pdf=|usr=020}}
| |
| − | {{tp|p=33127662|t=2020. Neither earlier nor late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study.|pdf=|usr=020}}
| |
| − | {{tp|p=33084021|t=2020. Hemoadsorption cartridge and coronavirus disease 2019 infections: A case report and brief literature review.|pdf=|usr=020}}
| |
| − | {{tp|p=33136592|t=2020. Treatment of Cytokine Storm in COVID-19 Patients With Immunomodulatory Therapy.|pdf=|usr=020}}
| |
| − | {{tp|p=33099890|t=2020. COVID-19: A Case for Inhibiting NLRP3 Inflammasome, Suppression of Inflammation with Curcumin?|pdf=|usr=020}}
| |
| − | {{tp|p=33176395|t=2020. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety.|pdf=|usr=020}}
| |
| − | {{tp|p=33094998|t=2020. Flexible Synthetic Carbohydrate Receptors as Inhibitors of Viral Attachment.|pdf=|usr=020}}
| |
| − | {{tp|p=33073571|t=2020. Gold/Silver Hybrid Nanoparticles with Enduring Inhibition of Coronavirus Multiplication through Multisite Mechanisms.|pdf=|usr=020}}
| |
| − | {{tp|p=33169410|t=2020. Can BCG vaccine protect against COVID-19 via trained immunity and tolerogenesis?|pdf=|usr=020}}
| |
| − | {{tp|p=33166093|t=2020. Can immunological manipulation defeat SARS-CoV-2? Why G-CSF induced neutrophil expansion is worth a clinical trial: G-CSF treatment against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33023432|t=2020. Therapeutic Options for Treatment of COVID-19: A Review from Repur-posed Drugs to New Drug Targets.|pdf=|usr=020}}
| |
| − | {{tp|p=33034297|t=2020. Povidone-iodine and carrageenan are candidates for SARS-CoV-2 infection control.|pdf=|usr=020}}
| |
| − | {{tp|p=33174654|t=2020. Traditional Chinese Medicine as a complementary therapy in combat with COVID-19-A review of evidence-based research and clinical practice.|pdf=|usr=020}}
| |
| − | {{tp|p=33179983|t=2020. Inhalable Hydroxychloroquine Powders for Potential Treatment of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33164048|t=2020. Inhibition of SARS-CoV-2 in Vero cell cultures by peptide-conjugated morpholino oligomers.|pdf=|usr=020}}
| |
| − | {{tp|p=33036548|t=2020. Molecular modeling study of tectoquinone and acteoside from Tectona grandis linn: a new SARS-CoV-2 main protease inhibitor against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33030105|t=2020. Molecular dynamics analysis predicts ritonavir and naloxegol strongly block the SARS-CoV-2 spike protein-hACE2 binding.|pdf=|usr=020}}
| |
| − | {{tp|p=33030102|t=2020. Finding potent inhibitors for COVID-19 main protease (M(pro)): an in silico approach using SARS-CoV-3CL protease inhibitors for combating CORONA.|pdf=|usr=020}}
| |
| − | {{tp|p=33078675|t=2020. Potential therapeutic effect of turmeric contents against SARS-CoV-2 compared with experimental COVID-19 therapies: in silico study.|pdf=|usr=020}}
| |
| − | {{tp|p=33047658|t=2020. Cysteine focused covalent inhibitors against the main protease of SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33140690|t=2020. DFT and docking studies of designed conjugates of noscapines & repurposing drugs: promising inhibitors of main protease of SARS-CoV-2 and falcipan-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33115586|t=2020. Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.|pdf=|usr=020}}
| |
| − | {{tp|p=33086298|t=2020. An Old Method as an Aid on the Novel Coronavirus.|pdf=|usr=020}}
| |
| − | {{tp|p=33164606|t=2020. COVID-19 during Pregnancy and Postpartum.|pdf=|usr=020}}
| |
| − | {{tp|p=33171544|t=2020. Food-derived antioxidants and COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33064152|t=2020. Postapproval Vaccine Safety Surveillance for COVID-19 Vaccines in the US.|pdf=|usr=020}}
| |
| − | {{tp|p=33064145|t=2020. Answering Key Questions About COVID-19 Vaccines.|pdf=|usr=020}}
| |
| − | {{tp|p=33064144|t=2020. Postlicensure Evaluation of COVID-19 Vaccines.|pdf=|usr=020}}
| |
| − | {{tp|p=33165621|t=2020. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.|pdf=|usr=020}}
| |
| − | {{tp|p=33180097|t=2020. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.|pdf=|usr=020}}
| |
| − | {{tp|p=33085870|t=2020. Audio Interview: Tocilizumab and Covid-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33053301|t=2020. Audio Interview: Vaccinology and Covid-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33028965|t=2020. Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters.|pdf=|usr=020}}
| |
| − | {{tp|p=33121282|t=2020. Potential of Ficus microcarpa metabolites against SARS-CoV-2 main protease supported by docking studies.|pdf=|usr=020}}
| |
| − | {{tp|p=32719377|t=2020. mRNA vaccines: intellectual property landscape.|pdf=|usr=020}}
| |
| − | {{tp|p=33045718|t=2020. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.|pdf=|usr=020}}
| |
| − | {{tp|p=33082543|t=2020. How obesity could create problems for a COVID vaccine.|pdf=|usr=020}}
| |
| − | {{tp|p=33082537|t=2020. COVID-19 vaccines: time to talk about the uncertainties.|pdf=|usr=020}}
| |
| − | {{tp|p=33077943|t=2020. All eyes on a hurdle race for a SARS-CoV-2 vaccine.|pdf=|usr=020}}
| |
| − | {{tp|p=33057226|t=2020. How anti-ageing drugs could boost COVID vaccines in older people.|pdf=|usr=020}}
| |
| − |
| |
| − | {{tp|p=33067179|t=2020. Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33055099|t=2020. Covid-19: Eli Lilly pauses antibody trial for safety reasons.|pdf=|usr=020}}
| |
| − | {{tp|p=33051241|t=2020. Covid-19: Johnson and Johnson vaccine trial is paused because of unexplained illness in participant.|pdf=|usr=020}}
| |
| − | {{tp|p=33168564|t=2020. Covid-19 vaccines: Should we allow human challenge studies to infect healthy volunteers with SARS-CoV-2?|pdf=|usr=020}}
| |
| − | {{tp|p=33168562|t=2020. Covid-19: Vaccine candidate may be more than 90% effective, interim results indicate.|pdf=|usr=020}}
| |
| − | {{tp|p=33153979|t=2020. Covid-19: NHS hospitals are urged to recruit more patients to Recovery trial to find what treatments work.|pdf=|usr=020}}
| |
| − | {{tp|p=33125791|t=2020. Risk assessment of therapeutic agents under consideration to treat COVID-19 in paediatric patients and pregnant women.|pdf=|usr=020}}
| |
| − | {{tp|p=33119136|t=2020. Challenges of drug development during the COVID-19 pandemic: key considerations for clinical trial designs.|pdf=|usr=020}}
| |
| − | {{tp|p=33085781|t=2020. Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis.|pdf=|usr=020}}
| |
| − | {{tp|p=33164544|t=2020. Ventricular repolarization indexes in patients treated with hydroxychloroquine - azithromycin combination for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=6135|t=1976. Purine catabolism in man: characterization of placental microsomal 5'-nucleotidase.|pdf=|usr=020}}
| |
| − | {{tp|p=33040779|t=2020. Interleukin-6 role in the severity of COVID-19 and intensive care unit stay length.|pdf=|usr=020}}
| |
| − | {{tp|p=33140889|t=2020. Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33031500|t=2020. Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33165503|t=2020. Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults.|pdf=|usr=020}}
| |
| − | {{tp|p=33159196|t=2020. Hydroxychloroquine for Prevention of SARS-CoV-2 Infection: challenges to trial conduct during the global pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33158957|t=2020. Preventing vitamin D deficiency during the COVID-19 pandemic: UK definitions of vitamin D sufficiency and recommended supplement dose are set too low.|pdf=|usr=020}}
| |
| − | {{tp|p=33135607|t=2020. Exploring the Potential Mechanism of Shufeng Jiedu Capsule for Treating COVID-19 by Comprehensive Network Pharmacological Approaches and Molecular Docking Validation.|pdf=|usr=020}}
| |
| − | {{tp|p=33106140|t=2020. Mechanistic Insights to the Binding of Antibody CR3022 Against RBD from SARS-CoV and HCoV-19/SARS-CoV-2: A Computational Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33155887|t=2020. A Computational Approach for Identifying Potential Phytochemicals Against Non-structural Protein 1 (Nsp1) of SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33172372|t=2020. Tinocordiside from Tinospora cordifolia (Giloy) May Curb SARS-CoV-2 Contagion by Disrupting the Electrostatic Interactions between Host ACE2 and Viral S-Protein Receptor Binding Domain.|pdf=|usr=020}}
| |
| − | {{tp|p=33109057|t=2020. Molecular Docking Studies of Bioactive Nicotiflorin against 6W63 Novel Coronavirus 2019 (COVID-19).|pdf=|usr=020}}
| |
| − | {{tp|p=33093279|t=2020. Almitrine Infusion in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Acute Respiratory Distress Syndrome: A Single-Center Observational Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33109061|t=2020. COVID-19 Infection and Vitamin D: Current Scenario and Future Prospects.|pdf=|usr=020}}
| |
| − | {{tp|p=33109030|t=2020. COVID-19: innovative antiviral drugs required for long-term prevention and control of coronavirus diseases.|pdf=|usr=020}}
| |
| − | {{tp|p=33109028|t=2020. Natural Products in Mitigation of SARS CoV Infections.|pdf=|usr=020}}
| |
| − | {{tp|p=33109027|t=2020. Recent Advances towards Drug Design Targeting the Protease of 2019 novel coronavirus (2019-nCoV).|pdf=|usr=020}}
| |
| − | {{tp|p=33109026|t=2020. COVID-19 vaccine race: analysis of age-dependent immune responses against SARS-CoV-2 indicates that more than just one strategy may be needed.|pdf=|usr=020}}
| |
| − | {{tp|p=33106134|t=2020. Evidence and the main adverse effects regarding drug therapies in the war against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33143619|t=2020. Rediscovery of caffeine: an excellent drug for improving patient outcomes while fighting WARS.|pdf=|usr=020}}
| |
| − | {{tp|p=32941186|t=2020. Obesity, vitamin D deficiency and old age a serious combination with respect to coronavirus disease-2019 severity and outcome.|pdf=|usr=020}}
| |
| − | {{tp|p=33100248|t=2020. Effectiveness of steroid treatment for SARS-CoV-2 pneumonia with COP-like reaction: a case report.|pdf=|usr=020}}
| |
| − | {{tp|p=32893468|t=2020. Efforts towards a COVID-19 vaccine.|pdf=|usr=020}}
| |
| − | {{tp|p=33044166|t=2020. Revisiting cardiac safety of hydroxychloroquine in rheumatological diseases during COVID-19 era: Facts and myths.|pdf=|usr=020}}
| |
| − | {{tp|p=33047822|t=2020. Imposed mutational meltdown as an antiviral strategy.|pdf=|usr=020}}
| |
| − |
| |
| − | {{tp|p=33067179|t=2020. Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33055099|t=2020. Covid-19: Eli Lilly pauses antibody trial for safety reasons.|pdf=|usr=020}}
| |
| − | {{tp|p=33051241|t=2020. Covid-19: Johnson and Johnson vaccine trial is paused because of unexplained illness in participant.|pdf=|usr=020}}
| |
| − | {{tp|p=33168564|t=2020. Covid-19 vaccines: Should we allow human challenge studies to infect healthy volunteers with SARS-CoV-2?|pdf=|usr=020}}
| |
| − | {{tp|p=33168562|t=2020. Covid-19: Vaccine candidate may be more than 90% effective, interim results indicate.|pdf=|usr=020}}
| |
| − | {{tp|p=33153979|t=2020. Covid-19: NHS hospitals are urged to recruit more patients to Recovery trial to find what treatments work.|pdf=|usr=020}}
| |
| − | {{tp|p=33125791|t=2020. Risk assessment of therapeutic agents under consideration to treat COVID-19 in paediatric patients and pregnant women.|pdf=|usr=020}}
| |
| − | {{tp|p=33119136|t=2020. Challenges of drug development during the COVID-19 pandemic: key considerations for clinical trial designs.|pdf=|usr=020}}
| |
| − | {{tp|p=33085781|t=2020. Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis.|pdf=|usr=020}}
| |
| − | {{tp|p=33164544|t=2020. Ventricular repolarization indexes in patients treated with hydroxychloroquine - azithromycin combination for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=6135|t=1976. Purine catabolism in man: characterization of placental microsomal 5'-nucleotidase.|pdf=|usr=020}}
| |
| − | {{tp|p=33040779|t=2020. Interleukin-6 role in the severity of COVID-19 and intensive care unit stay length.|pdf=|usr=020}}
| |
| − | {{tp|p=33140889|t=2020. Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33031500|t=2020. Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33165503|t=2020. Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults.|pdf=|usr=020}}
| |
| − | {{tp|p=33159196|t=2020. Hydroxychloroquine for Prevention of SARS-CoV-2 Infection: challenges to trial conduct during the global pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33158957|t=2020. Preventing vitamin D deficiency during the COVID-19 pandemic: UK definitions of vitamin D sufficiency and recommended supplement dose are set too low.|pdf=|usr=020}}
| |
| − | {{tp|p=33135607|t=2020. Exploring the Potential Mechanism of Shufeng Jiedu Capsule for Treating COVID-19 by Comprehensive Network Pharmacological Approaches and Molecular Docking Validation.|pdf=|usr=020}}
| |
| − | {{tp|p=33106140|t=2020. Mechanistic Insights to the Binding of Antibody CR3022 Against RBD from SARS-CoV and HCoV-19/SARS-CoV-2: A Computational Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33155887|t=2020. A Computational Approach for Identifying Potential Phytochemicals Against Non-structural Protein 1 (Nsp1) of SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33172372|t=2020. Tinocordiside from Tinospora cordifolia (Giloy) May Curb SARS-CoV-2 Contagion by Disrupting the Electrostatic Interactions between Host ACE2 and Viral S-Protein Receptor Binding Domain.|pdf=|usr=020}}
| |
| − | {{tp|p=33109057|t=2020. Molecular Docking Studies of Bioactive Nicotiflorin against 6W63 Novel Coronavirus 2019 (COVID-19).|pdf=|usr=020}}
| |
| − | {{tp|p=33093279|t=2020. Almitrine Infusion in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Acute Respiratory Distress Syndrome: A Single-Center Observational Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33109061|t=2020. COVID-19 Infection and Vitamin D: Current Scenario and Future Prospects.|pdf=|usr=020}}
| |
| − | {{tp|p=33109030|t=2020. COVID-19: innovative antiviral drugs required for long-term prevention and control of coronavirus diseases.|pdf=|usr=020}}
| |
| − | {{tp|p=33109028|t=2020. Natural Products in Mitigation of SARS CoV Infections.|pdf=|usr=020}}
| |
| − | {{tp|p=33109027|t=2020. Recent Advances towards Drug Design Targeting the Protease of 2019 novel coronavirus (2019-nCoV).|pdf=|usr=020}}
| |
| − | {{tp|p=33109026|t=2020. COVID-19 vaccine race: analysis of age-dependent immune responses against SARS-CoV-2 indicates that more than just one strategy may be needed.|pdf=|usr=020}}
| |
| − | {{tp|p=33106134|t=2020. Evidence and the main adverse effects regarding drug therapies in the war against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33143619|t=2020. Rediscovery of caffeine: an excellent drug for improving patient outcomes while fighting WARS.|pdf=|usr=020}}
| |
| − | {{tp|p=32941186|t=2020. Obesity, vitamin D deficiency and old age a serious combination with respect to coronavirus disease-2019 severity and outcome.|pdf=|usr=020}}
| |
| − | {{tp|p=33100248|t=2020. Effectiveness of steroid treatment for SARS-CoV-2 pneumonia with COP-like reaction: a case report.|pdf=|usr=020}}
| |
| − | {{tp|p=32893468|t=2020. Efforts towards a COVID-19 vaccine.|pdf=|usr=020}}
| |
| − | {{tp|p=33044166|t=2020. Revisiting cardiac safety of hydroxychloroquine in rheumatological diseases during COVID-19 era: Facts and myths.|pdf=|usr=020}}
| |
| − | {{tp|p=33047822|t=2020. Imposed mutational meltdown as an antiviral strategy.|pdf=|usr=020}}
| |
| − |
| |
| − | {{tp|p=33150525|t=2020. Rescue therapy with inhaled nitric oxide and almitrine in COVID-19 patients with severe acute respiratory distress syndrome.|pdf=|usr=020}}
| |
| − | {{tp|p=33090877|t=2020. Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials.|pdf=|usr=020}}
| |
| − | {{tp|p=33074704|t=2020. COVID-19 Vaccine: What Physicians Need to Know.|pdf=|usr=020}}
| |
| − | {{tp|p=33085507|t=2020. Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=32950986|t=2020. Switching Host Metabolism as an Approach to Dampen SARS-CoV-2 Infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33007381|t=2020. Androgen deprivation therapy in unlikely to be effective for treatment of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=32954754|t=2020. Xuebijing injection in the treatment of COVID-19: a retrospective case-control study.|pdf=|usr=020}}
| |
| − | {{tp|p=32921099|t=2020. Hydroxychloroquine for the treatment of COVID-19: the importance of scrutiny of positive trials.|pdf=|usr=020}}
| |
| − | {{tp|p=33050459|t=2020. May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients?|pdf=|usr=020}}
| |
| − | {{tp|p=33091434|t=2020. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.|pdf=|usr=020}}
| |
| − | {{tp|p=33173252|t=2020. Titanium (IV) complexes of some tetra-dentate symmetrical bis-Schiff bases of 1,6-hexanediamine: Synthesis, characterization, and in silico prediction of potential inhibitor against coronavirus (SARS-CoV-2).|pdf=|usr=020}}
| |
| − | {{tp|p=33134963|t=2020. Extracorporeal Hemoperfusion as a Potential Therapeutic Option for Severe COVID-19 patients; a Narrative Review.|pdf=|usr=020}}
| |
| − | {{tp|p=33160751|t=2020. Role of Systemic and Nasal Glucocorticoid Treatment in the Regulation of the Inflammatory Response in Patients with SARS-Cov-2 Infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33168195|t=2020. GK1: An Alternative Treatment to Control the Respiratory Complications During COVID19.|pdf=|usr=020}}
| |
| − | {{tp|p=33047848|t=2020. Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33177651|t=2020. Engineered trimeric ACE2 binds viral spike protein and locks it in "Three-up" conformation to potently inhibit SARS-CoV-2 infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33181114|t=2020. In silico analysis of selected alkaloids against main protease (M(pro)) of SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33031623|t=2020. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.|pdf=|usr=020}}
| |
| − | {{tp|p=33104777|t=2020. Avifavir in Treating Patients with Moderate Covid 19.|pdf=|usr=020}}
| |
| − | {{tp|p=33103195|t=2020. Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33079180|t=2020. Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab.|pdf=|usr=020}}
| |
| − | {{tp|p=33075124|t=2020. Favipiravir as an antiviral agent in COVID-19: same script, different cast?|pdf=|usr=020}}
| |
| − | {{tp|p=33068425|t=2020. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial.|pdf=|usr=020}}
| |
| − | {{tp|p=33053155|t=2020. Survival analysis of treatment efficacy in comparative COVID-19 studies.|pdf=|usr=020}}
| |
| − | {{tp|p=33038227|t=2020. Convalescent plasma for patients with severe COVID-19: a matched cohort study.|pdf=|usr=020}}
| |
| − | {{tp|p=33103512|t=2020. The probiotic Bifidobacterium in the management of Coronavirus: A theoretical basis.|pdf=|usr=020}}
| |
| − | {{tp|p=33045858|t=2020. Cationic drugs and COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33130197|t=2020. The art of the possible in approaching efficacy trials for COVID19 convalescent plasma.|pdf=|usr=020}}
| |
| − | {{tp|p=33130203|t=2020. Role of favipiravir in the treatment of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33130195|t=2020. Why we should be more careful using hydroxychloroquine in influenza season?|pdf=|usr=020}}
| |
| − | {{tp|p=33129966|t=2020. Could SARS-CoV-2-induced lung injury be attenuated by vitamin D?|pdf=|usr=020}}
| |
| − | {{tp|p=33127507|t=2020. Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study.|pdf=|usr=020}}
| |
| − | {{tp|p=33115682|t=2020. Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia.|pdf=|usr=020}}
| |
| − | {{tp|p=33100779|t=2020. A prospective clinical study of an Ayurveda regimen in COVID 19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33071521|t=2020. Outcomes of Ayurvedic care in a COVID-19 patient with hypoxia - A Case Report.|pdf=|usr=020}}
| |
| − | {{tp|p=33094891|t=2020. Discovery of novel pyrazole derivatives as a potent anti-inflammatory agent in RAW264.7 cells via inhibition of NF-kB for possible benefit against SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33184246|t=2020. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods.|pdf=|usr=020}}
| |
| − | {{tp|p=33167413|t=2020. Vaccinomics and Adversomics in the Era of Precision Medicine: A Review Based on HBV, MMR, HPV, and COVID-19 Vaccines.|pdf=|usr=020}}
| |
| − | {{tp|p=33089717|t=2020. Antiviral Activity of Reagents in Mouth Rinses against SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33041320|t=2020. Research on drugs and vaccines for COVID-19 should be conducted and published with caution.|pdf=|usr=020}}
| |
| − | {{tp|p=33178638|t=2020. Physical exercise for strengthening innate immunity during COVID-19 pandemic: 4th series of scientific evidence.|pdf=|usr=020}}
| |
| − | {{tp|p=33064151|t=2020. SARS-CoV-2 vaccine development, access, and equity.|pdf=|usr=020}}
| |
| − | {{tp|p=32944185|t=2020. Systematic review of extracellular vesicle-based treatments for lung injury: are EVs a potential therapy for COVID-19?|pdf=|usr=020}}
| |
| − | {{tp|p=33129444|t=2020. In Pursuit of a SARS-CoV-2 Vaccine.|pdf=|usr=020}}
| |
| − | {{tp|p=33141358|t=2020. A comprehensive review on promising anti-viral therapeutic candidates identified against main protease from SARS-CoV-2 through various computational methods.|pdf=|usr=020}}
| |
| − | {{tp|p=33075521|t=2020. Ototoxicity prevention during the SARS-CoV-2 (COVID-19) emergency.|pdf=|usr=020}}
| |
| − | {{tp|p=33065330|t=2020. Possible application of high-dose vitamin C in the prevention and therapy of coronavirus infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33134398|t=2020. Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping.|pdf=|usr=020}}
| |
| − | {{tp|p=33062720|t=2020. Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine.|pdf=|usr=020}}
| |
| − | {{tp|p=33115658|t=2020. Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33031085|t=2020. Nitazoxanide against COVID-19 in three explorative scenarios.|pdf=|usr=020}}
| |
| − | {{tp|p=33175709|t=2020. Umbilical cord blood-derived mesenchymal stem cells in treating a critically ill COVID-19 patient.|pdf=|usr=020}}
| |
| − | {{tp|p=33069626|t=2020. Effects of Tanreqing Capsule on the negative conversion time of nucleic acid in patients with COVID-19: A retrospective cohort study.|pdf=|usr=020}}
| |
| − | {{tp|p=33060041|t=2020. Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review.|pdf=|usr=020}}
| |
| − | {{tp|p=33054978|t=2020. Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia.|pdf=|usr=020}}
| |
| − | {{tp|p=33071354|t=2020. Fenoterol and dobutamine as COVID-19 main protease inhibitors: A virtual screening study.|pdf=|usr=020}}
| |
| − | {{tp|p=33148446|t=2020. Vitamin D Clinical Pharmacology: Relevance to COVID-19 Pathogenesis.|pdf=|usr=020}}
| |
| − | {{tp|p=33088307|t=2020. Bioinformatics analysis of Wuhan novel coronavirus pathogen: A clue for finding antiviral drug against Wuhan novel coronavirus.|pdf=|usr=020}}
| |
| − | {{tp|p=33065275|t=2020. Vitamin D and survival in COVID-19 patients: A quasi-experimental study.|pdf=|usr=020}}
| |
| − | {{tp|p=33169114|t=2020. Why will it never be known if convalescent plasma is effective for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33062586|t=2020. Corticosteroids: A Controversial Therapy for Coronavirus Disease 2019.|pdf=|usr=020}}
| |
| − | {{tp|p=33087150|t=2020. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.|pdf=|usr=020}}
| |
| − | {{tp|p=33059719|t=2020. A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals.|pdf=|usr=020}}
| |
| − | {{tp|p=33068703|t=2021. Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=32971042|t=2020. What can we expect from first-generation COVID-19 vaccines?|pdf=|usr=020}}
| |
| − | {{tp|p=33065034|t=2020. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates.|pdf=|usr=020}}
| |
| − | {{tp|p=33069282|t=2020. A promising inactivated whole-virion SARS-CoV-2 vaccine.|pdf=|usr=020}}
| |
| − | {{tp|p=33069281|t=2020. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.|pdf=|usr=020}}
| |
| − | {{tp|p=32979327|t=2020. The arrival of Sputnik V.|pdf=|usr=020}}
| |
| − | {{tp|p=33121991|t=2020. Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33131749|t=2020. Short-term high-dose gavage of hydroxychloroquine changes gut microbiota but not the intestinal integrity and immunological responses in mice.|pdf=|usr=020}}
| |
| − | {{tp|p=33049279|t=2020. Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics.|pdf=|usr=020}}
| |
| − | {{tp|p=33189817|t=2020. The nucleocapsid protein of zoonotic betacoronaviruses is an attractive target for antiviral drug discovery.|pdf=|usr=020}}
| |
| − | {{tp|p=33035581|t=2020. Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?|pdf=|usr=020}}
| |
| − | {{tp|p=33153626|t=2020. Recruitment Strategy for Potential COVID-19 Convalescent Plasma Donors.|pdf=|usr=020}}
| |
| − | {{tp|p=33163895|t=2020. The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33082259|t=2020. Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.|pdf=|usr=020}}
| |
| − | {{tp|p=33067179|t=2020. Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33055099|t=2020. Covid-19: Eli Lilly pauses antibody trial for safety reasons.|pdf=|usr=020}}
| |
| − | {{tp|p=33051241|t=2020. Covid-19: Johnson and Johnson vaccine trial is paused because of unexplained illness in participant.|pdf=|usr=020}}
| |
| − | {{tp|p=33168564|t=2020. Covid-19 vaccines: Should we allow human challenge studies to infect healthy volunteers with SARS-CoV-2?|pdf=|usr=020}}
| |
| − | {{tp|p=33168562|t=2020. Covid-19: Vaccine candidate may be more than 90% effective, interim results indicate.|pdf=|usr=020}}
| |
| − | {{tp|p=33153979|t=2020. Covid-19: NHS hospitals are urged to recruit more patients to Recovery trial to find what treatments work.|pdf=|usr=020}}
| |
| − | {{tp|p=33125791|t=2020. Risk assessment of therapeutic agents under consideration to treat COVID-19 in paediatric patients and pregnant women.|pdf=|usr=020}}
| |
| − | {{tp|p=33119136|t=2020. Challenges of drug development during the COVID-19 pandemic: key considerations for clinical trial designs.|pdf=|usr=020}}
| |
| − | {{tp|p=33085781|t=2020. Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis.|pdf=|usr=020}}
| |
| − | {{tp|p=33164544|t=2020. Ventricular repolarization indexes in patients treated with hydroxychloroquine - azithromycin combination for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=6135|t=1976. Purine catabolism in man: characterization of placental microsomal 5'-nucleotidase.|pdf=|usr=020}}
| |
| − | {{tp|p=33040779|t=2020. Interleukin-6 role in the severity of COVID-19 and intensive care unit stay length.|pdf=|usr=020}}
| |
| − | {{tp|p=33140889|t=2020. Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33031500|t=2020. Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33165503|t=2020. Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults.|pdf=|usr=020}}
| |
| − | {{tp|p=33159196|t=2020. Hydroxychloroquine for Prevention of SARS-CoV-2 Infection: challenges to trial conduct during the global pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33158957|t=2020. Preventing vitamin D deficiency during the COVID-19 pandemic: UK definitions of vitamin D sufficiency and recommended supplement dose are set too low.|pdf=|usr=020}}
| |
| − | {{tp|p=33135607|t=2020. Exploring the Potential Mechanism of Shufeng Jiedu Capsule for Treating COVID-19 by Comprehensive Network Pharmacological Approaches and Molecular Docking Validation.|pdf=|usr=020}}
| |
| − | {{tp|p=33106140|t=2020. Mechanistic Insights to the Binding of Antibody CR3022 Against RBD from SARS-CoV and HCoV-19/SARS-CoV-2: A Computational Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33155887|t=2020. A Computational Approach for Identifying Potential Phytochemicals Against Non-structural Protein 1 (Nsp1) of SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33172372|t=2020. Tinocordiside from Tinospora cordifolia (Giloy) May Curb SARS-CoV-2 Contagion by Disrupting the Electrostatic Interactions between Host ACE2 and Viral S-Protein Receptor Binding Domain.|pdf=|usr=020}}
| |
| − | {{tp|p=33109057|t=2020. Molecular Docking Studies of Bioactive Nicotiflorin against 6W63 Novel Coronavirus 2019 (COVID-19).|pdf=|usr=020}}
| |
| − | {{tp|p=33093279|t=2020. Almitrine Infusion in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Acute Respiratory Distress Syndrome: A Single-Center Observational Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33109061|t=2020. COVID-19 Infection and Vitamin D: Current Scenario and Future Prospects.|pdf=|usr=020}}
| |
| − | {{tp|p=33109030|t=2020. COVID-19: innovative antiviral drugs required for long-term prevention and control of coronavirus diseases.|pdf=|usr=020}}
| |
| − | {{tp|p=33109028|t=2020. Natural Products in Mitigation of SARS CoV Infections.|pdf=|usr=020}}
| |
| − | {{tp|p=33109027|t=2020. Recent Advances towards Drug Design Targeting the Protease of 2019 novel coronavirus (2019-nCoV).|pdf=|usr=020}}
| |
| − | {{tp|p=33109026|t=2020. COVID-19 vaccine race: analysis of age-dependent immune responses against SARS-CoV-2 indicates that more than just one strategy may be needed.|pdf=|usr=020}}
| |
| − | {{tp|p=33106134|t=2020. Evidence and the main adverse effects regarding drug therapies in the war against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33143619|t=2020. Rediscovery of caffeine: an excellent drug for improving patient outcomes while fighting WARS.|pdf=|usr=020}}
| |
| − | {{tp|p=32941186|t=2020. Obesity, vitamin D deficiency and old age a serious combination with respect to coronavirus disease-2019 severity and outcome.|pdf=|usr=020}}
| |
| − | {{tp|p=33100248|t=2020. Effectiveness of steroid treatment for SARS-CoV-2 pneumonia with COP-like reaction: a case report.|pdf=|usr=020}}
| |
| − | {{tp|p=32893468|t=2020. Efforts towards a COVID-19 vaccine.|pdf=|usr=020}}
| |
| − | {{tp|p=33044166|t=2020. Revisiting cardiac safety of hydroxychloroquine in rheumatological diseases during COVID-19 era: Facts and myths.|pdf=|usr=020}}
| |
| − | {{tp|p=33047822|t=2020. Imposed mutational meltdown as an antiviral strategy.|pdf=|usr=020}}
| |
| − |
| |
| − | {{tp|p=33078087|t=2020. Vitamin D Update.|pdf=|usr=020}}
| |
| − | {{tp|p=33125628|t=2020. Medical Nutrition Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection in a Non-critical Care Setting: Knowledge in Progress.|pdf=|usr=020}}
| |
| − | {{tp|p=33128927|t=2020. Probable positive effects of the photobiomodulation as an adjunctive treatment in COVID-19: A systematic review.|pdf=|usr=020}}
| |
| − | {{tp|p=33098610|t=2020. CD147 inhibitors as a treatment for melanoma: Promising agents against SARS-CoV-2 infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33032231|t=2020. Ivermectin in COVID-19: What do we know?|pdf=|usr=020}}
| |
| − | {{tp|p=33120281|t=2020. Statins and SARS-CoV-2 disease: Current concepts and possible benefits.|pdf=|usr=020}}
| |
| − | {{tp|p=33113472|t=2020. An update on the global vaccine development for coronavirus.|pdf=|usr=020}}
| |
| − | {{tp|p=33052538|t=2020. Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions.|pdf=|usr=020}}
| |
| − | {{tp|p=33052537|t=2020. A Response To: Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions.|pdf=|usr=020}}
| |
| − | {{tp|p=33133998|t=2020. COVID-19-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes on SGLT2 inhibitor: a case report.|pdf=|usr=020}}
| |
| − | {{tp|p=33043284|t=2020. Sarilumab use in severe SARS-CoV-2 pneumonia.|pdf=|usr=020}}
| |
| − | {{tp|p=33173853|t=2020. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study.|pdf=|usr=020}}
| |
| − | {{tp|p=33078138|t=2020. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort).|pdf=|usr=020}}
| |
| − | {{tp|p=33043052|t=2020. Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space.|pdf=|usr=020}}
| |
| − | {{tp|p=33117441|t=2020. Short-term Hydroxychloroquine in COVID-19 Infection in People With or Without Metabolic Syndrome - Clearing Safety Issues and Good Clinical Practice.|pdf=|usr=020}}
| |
| − | {{tp|p=33117437|t=2020. Testosterone in COVID-19 - Foe, Friend or Fatal Victim?|pdf=|usr=020}}
| |
| − | {{tp|p=33183404|t=2020. Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020.|pdf=|usr=020}}
| |
| − | {{tp|p=33123207|t=2020. Screening for Anti-Influenza Actives of Prefractionated Traditional Chinese Medicines.|pdf=|usr=020}}
| |
| − | {{tp|p=33101440|t=2020. Traditional Herbal Medicine Candidates as Complementary Treatments for COVID-19: A Review of Their Mechanisms, Pros and Cons.|pdf=|usr=020}}
| |
| − | {{tp|p=33029165|t=2020. Investigating Potential Inhibitory Effect of Uncaria tomentosa (Cat's Claw) against the Main Protease 3CL(pro) of SARS-CoV-2 by Molecular Modeling.|pdf=|usr=020}}
| |
| − | {{tp|p=33088255|t=2020. Vitamin D supplementation in COVID-19: A friend or foe?|pdf=|usr=020}}
| |
| − | {{tp|p=33158784|t=2020. Evidence-based assessment of potential therapeutic effects of adjunct osteopathic medicine for multidisciplinary care of acute and convalescent COVID-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33046408|t=2020. Do saline water gargling and nasal irrigation confer protection against COVID-19?|pdf=|usr=020}}
| |
| − | {{tp|p=33091573|t=2020. Heme oxygenase-1 modulation: A potential therapeutic target for COVID-19 and associated complications.|pdf=|usr=020}}
| |
| − | {{tp|p=33102461|t=2020. Co-aerosolized Pulmonary Surfactant and Ambroxol for COVID-19 ARDS Intervention: What Are We Waiting for?|pdf=|usr=020}}
| |
| − | {{tp|p=33194800|t=2020. Systems Biology Approaches for Therapeutics Development Against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33195080|t=2020. Identification of a New Potential SARS-COV-2 RNA-Dependent RNA Polymerase Inhibitor via Combining Fragment-Based Drug Design, Docking, Molecular Dynamics, and MM-PBSA Calculations.|pdf=|usr=020}}
| |
| − | {{tp|p=33195060|t=2020. Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain.|pdf=|usr=020}}
| |
| − | {{tp|p=33123544|t=2020. Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33072783|t=2020. Covid-19 Pandemic: Maximizing Future Vaccination Treatments Considering Aging and Frailty.|pdf=|usr=020}}
| |
| − | {{tp|p=33072781|t=2020. The Pipeline of Therapeutics Testing During the Emergency Phase of the COVID-19 Outbreak.|pdf=|usr=020}}
| |
| − | {{tp|p=33072773|t=2020. Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.|pdf=|usr=020}}
| |
| − | {{tp|p=33043030|t=2020. Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences.|pdf=|usr=020}}
| |
| − | {{tp|p=33192523|t=2020. Role of Traditional Chinese Medicine in the Management of Viral Pneumonia.|pdf=|usr=020}}
| |
| − | {{tp|p=33192506|t=2020. Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements.|pdf=|usr=020}}
| |
| − | {{tp|p=33192504|t=2020. Coronavirus-19: Possible Therapeutic Implications of Spironolactone and Dry Extract of Glycyrrhiza glabra L. (Licorice).|pdf=|usr=020}}
| |
| − | {{tp|p=33192503|t=2020. Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33178026|t=2020. Current Prevention of COVID-19: Natural Products and Herbal Medicine.|pdf=|usr=020}}
| |
| − | {{tp|p=33178016|t=2020. COVID-19 Outbreak: Pathogenesis, Current Therapies, and Potentials for Future Management.|pdf=|usr=020}}
| |
| − | {{tp|p=33178011|t=2020. Hydrogen: A Potential New Adjuvant Therapy for COVID-19 Patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33162891|t=2020. Vulnerabilities of the SARS-CoV-2 Virus to Proteotoxicity-Opportunity for Repurposed Chemotherapy of COVID-19 Infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33162887|t=2020. Targeting Neutrophils to Treat Acute Respiratory Distress Syndrome in Coronavirus Disease.|pdf=|usr=020}}
| |
| − | {{tp|p=33154723|t=2020. Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33132915|t=2020. Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33132913|t=2020. "Fei Yan No. 1" as a Combined Treatment for COVID-19: An Efficacy and Potential Mechanistic Study.|pdf=|usr=020}}
| |
| − | {{tp|p=33123014|t=2020. Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines.|pdf=|usr=020}}
| |
| − | {{tp|p=32974268|t=2020. Overview of the First 6 Months of Clinical Trials for COVID-19 Pharmacotherapy: The Most Studied Drugs.|pdf=|usr=020}}
| |
| − | {{tp|p=32903641|t=2020. Convalescent Plasma: A Potential Life-Saving Therapy for Coronavirus Disease 2019 (COVID-19).|pdf=|usr=020}}
| |
| − | {{tp|p=33187757|t=2020. What it will take to equitably distribute a COVID-19 vaccine.|pdf=|usr=020}}
| |
| − | {{tp|p=33105142|t=2020. Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33062058|t=2020. How to boost the immune defence prior to respiratory virus infections with the special focus on coronavirus infections.|pdf=|usr=020}}
| |
| − | {{tp|p=33041058|t=2020. Cytosorb filter: An adjunct for survival in the COVID-19 patient in cytokine storm? a case report.|pdf=|usr=020}}
| |
| − | {{tp|p=33163683|t=2020. Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins.|pdf=|usr=020}}
| |
| − | {{tp|p=33062945|t=2020. SARS-CoV-2 Interstitial Pneumonia Treated With Tocilizumab in a Patient Affected by Classical Hodgkin Lymphoma.|pdf=|usr=020}}
| |
| − | {{tp|p=33156739|t=2020. Recent advances in vaccine and immunotherapy for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=32900407|t=2020. Antimicrobial stewardship programs and convalescent plasma for COVID-19: A new paradigm for preauthorization?|pdf=|usr=020}}
| |
| − | {{tp|p=32938504|t=2020. Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33116688|t=2020. Flattening the Risk: Pre-Exposure Prophylaxis for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33061471|t=2020. Drugs for Multiple Sclerosis Activate Natural Killer Cells: Do They Protect Against COVID-19 Infection?|pdf=|usr=020}}
| |
| − | {{tp|p=33130005|t=2020. A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33132111|t=2020. Overlapping host pathways between SARS-CoV-2 and its potential copathogens: An in silico analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33102688|t=2020. In silico identification of drug candidates against COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33102687|t=2020. Applying computer simulations in battling with COVID-19, using pre-analyzed molecular and chemical data to face the pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33052313|t=2020. Chloroquine and hydroxychloroquine for combating COVID-19: Investigating efficacy and hypothesizing new formulations using Bio/chemoinformatics tools.|pdf=|usr=020}}
| |
| − | {{tp|p=33043110|t=2020. Exploration of surface glycoprotein to design multi-epitope vaccine for the prevention of Covid-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33169118|t=2020. Recovery of Four COVID-19 Patients via Ozonated Autohemotherapy.|pdf=|usr=020}}
| |
| − | {{tp|p=33160854|t=2020. Gender-associated difference following COVID-19 virus infection: Implications for thymosin alpha-1 therapy.|pdf=|usr=020}}
| |
| − | {{tp|p=33045577|t=2020. Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease.|pdf=|usr=020}}
| |
| − | {{tp|p=33162345|t=2020. Application value of artificial liver support system in the treatment of cytokine storm in patients with COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33129099|t=2020. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33091817|t=2020. Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital.|pdf=|usr=020}}
| |
| − | {{tp|p=33075713|t=2020. Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial.|pdf=|usr=020}}
| |
| − | {{tp|p=33080267|t=2020. Designed variants of ACE2-Fc that decouple anti-SARS-CoV-2 activities from unwanted cardiovascular effects.|pdf=|usr=020}}
| |
| − | {{tp|p=33165417|t=2020. Network pharmacology-based study of the molecular mechanisms of Qixuekang in treating COVID-19 during the recovery period.|pdf=|usr=020}}
| |
| − | {{tp|p=33113270|t=2020. Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease.|pdf=|usr=020}}
| |
| − | {{tp|p=33113232|t=2020. Generalized exanthema due to hydroxychloroquine as a popular drug during COVID-19 prophylaxis.|pdf=|usr=020}}
| |
| − | {{tp|p=33108703|t=2020. Can Tenofovir diphosphate be a candidate drug for Sars-Cov2? First clinical perspective.|pdf=|usr=020}}
| |
| − | {{tp|p=33064918|t=2020. COVID-19 infection threat in patients with high-risk non-muscle invasive bladder cancer receiving intravesical BCG therapy.|pdf=|usr=020}}
| |
| − | {{tp|p=33063447|t=2020. QTc prolongation among hydroxychloroquine sulfate-treated COVID-19 patients: An observational study.|pdf=|usr=020}}
| |
| − | {{tp|p=33115677|t=2020. HIV/SARS-CoV-2 co-infection: T cell profile, cytokine dynamics and role of exhausted lymphocytes.|pdf=|usr=020}}
| |
| − | {{tp|p=33075525|t=2020. Hydroxychloroquine safety outcome with an approved therapeutic protocol for COVID-19 outpatients in Saudi Arabia.|pdf=|usr=020}}
| |
| − | {{tp|p=33075529|t=2020. The unfinished story of hydroxychloroquine in COVID-19: the right anti-inflammatory dose at the right moment?|pdf=|usr=020}}
| |
| − | {{tp|p=33160064|t=2020. Arginine Depletion as a Therapeutic Approach for Patients with COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33157292|t=2020. Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation.|pdf=|usr=020}}
| |
| − | {{tp|p=33157287|t=2020. Therapeutic plasma exchange followed by convalescent plasma transfusion in critical COVID-19-An exploratory study.|pdf=|usr=020}}
| |
| − | {{tp|p=33186704|t=2020. CCR5 Inhibition in Critical COVID-19 Patients Decreases Inflammatory Cytokines, Increases CD8 T-Cells, and Decreases SARS-CoV2 RNA in Plasma by Day 14.|pdf=|usr=020}}
| |
| − | {{tp|p=33173434|t=2020. Herbal plants coordinate COVID-19 in multiple dimensions - An insight analysis for clinically applied remedies.|pdf=|usr=020}}
| |
| − | {{tp|p=33029094|t=2020. Investigating the mechanism of ShuFeng JieDu capsule for the treatment of novel Coronavirus pneumonia (COVID-19) based on network pharmacology.|pdf=|usr=020}}
| |
| − | {{tp|p=33156381|t=2020. Impact of late administration of corticosteroids in COVID-19 ARDS.|pdf=|usr=020}}
| |
| − | {{tp|p=33068241|t=2020. Remdesivir and COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33150537|t=2020. The mental health and well-being benefits of exercise during the COVID-19 pandemic: a cross-sectional study of medical students and newly qualified doctors in the UK.|pdf=|usr=020}}
| |
| − | {{tp|p=33083317|t=2020. Corticosteroids on the Management of Coronavirus Disease 2019 (COVID-19): A Systemic Review and Meta-Analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33070984|t=2020. Mitigating the transmission of infection and death due to SARS-CoV-2 through non-pharmaceutical interventions and repurposing drugs.|pdf=|usr=020}}
| |
| − | {{tp|p=33043282|t=2020. Furin: A Potential Therapeutic Target for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33134887|t=2020. Robust and Specific Secretory IgA Against SARS-CoV-2 Detected in Human Milk.|pdf=|usr=020}}
| |
| − | {{tp|p=33103068|t=2020. Integrative Transcriptome Analyses Empower the Anti-COVID-19 Drug Arsenal.|pdf=|usr=020}}
| |
| − | {{tp|p=33010257|t=2020. IL-6 serum levels predict severity and response to Tocilizumab in COVID-19: an observational study.|pdf=|usr=020}}
| |
| − | {{tp|p=33040416|t=2020. Plasma exchange therapy and COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33045077|t=2020. Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?|pdf=|usr=020}}
| |
| − | {{tp|p=33128490|t=2020. Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network meta-analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33148157|t=2020. Can Nutrition Play a Role as a Stimulant for COVID 19 in Children?|pdf=|usr=020}}
| |
| − | {{tp|p=33077678|t=2020. Prospects for a safe COVID-19 vaccine.|pdf=|usr=020}}
| |
| − | {{tp|p=33037066|t=2020. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.|pdf=|usr=020}}
| |
| − | {{tp|p=32972994|t=2020. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.|pdf=|usr=020}}
| |
| − | {{tp|p=33053601|t=2020. Early phase dose-finding trials in virology.|pdf=|usr=020}}
| |
| − | {{tp|p=33165216|t=2020. Development and validation of a simple and rapid UHPLC-MS/MS method for the quantification of hydroxychloroquine in plasma and blood samples in the emergency context of SARS-CoV-2 pandemic.|pdf=|usr=020}}
| |
| − | {{tp|p=33073895|t=2020. Safety and efficacy of COVID-19 convalescent plasma in severe pulmonary disease: A report of 17 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33125158|t=2020. Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33104267|t=2020. Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.|pdf=|usr=020}}
| |
| − | {{tp|p=32931666|t=2020. Hyperbaric oxygen therapy for COVID-19 patients with respiratory distress: treated cases versus propensity-matched controls.|pdf=|usr=020}}
| |
| − | {{tp|p=32894904|t=2020. [Immune imbalance and immunoregulatory treatment of COVID-19].|pdf=|usr=020}}
| |
| − | {{tp|p=33137863|t=2020. [Potential therapeutic drugs for novel coronavirus pneumonia].|pdf=|usr=020}}
| |
| − |
| |
| − | {{tp|p=33078035|t=2020. Modeling of the adsorption of a protein-fragment on kaolinite with potential antiviral activity.|pdf=|usr=020}}
| |
| − | {{tp|p=33072222|t=2020. Structure-Based Design of Novel Peptidomimetics Targeting the SARS-CoV-2 Spike Protein.|pdf=|usr=020}}
| |
| − | {{tp|p=33107132|t=2020. Phase 1 trial for treatment of COVID-19 patients with pulmonary fibrosis using hESC-IMRCs.|pdf=|usr=020}}
| |
| − | {{tp|p=33107123|t=2020. First case of COVID-19 infused with hESC derived immunity- and matrix-regulatory cells.|pdf=|usr=020}}
| |
| − | {{tp|p=33098357|t=2020. Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis.|pdf=|usr=020}}
| |
| − | {{tp|p=33027617|t=2020. An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain.|pdf=|usr=020}}
| |
| − | {{tp|p=33163980|t=2020. Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells.|pdf=|usr=020}}
| |
| − | {{tp|p=33031791|t=2020. Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33121920|t=2020. Race to arsenal COVID-19 therapeutics: Current alarming status and future directions.|pdf=|usr=020}}
| |
| − | {{tp|p=33098839|t=2020. System biological investigations of hydroxychloroquine and azithromycin targets and their implications in QT interval prolongation.|pdf=|usr=020}}
| |
| − | {{tp|p=33052144|t=2020. Identification of potential inhibitors of SARS-CoV-2 papain-like protease from tropane alkaloids from Schizanthus porrigens: A molecular docking study.|pdf=|usr=020}}
| |
| − | {{tp|p=33041350|t=2020. Neuroprotective immunity by essential nutrient "Choline" for the prevention of SARS CoV2 infections: An in silico study by molecular dynamics approach.|pdf=|usr=020}}
| |
| − | {{tp|p=33029193|t=2020. Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy.|pdf=|usr=020}}
| |
| − | {{tp|p=33101604|t=2020. Side chain similarity comparisons for integrated drug repositioning and potential toxicity assessments in epidemic response scenarios: The case for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33102987|t=2020. Xanthene based hybrid analogues to inhibit protease of novel corona Virus: Molecular docking and ADMET studies.|pdf=|usr=020}}
| |
| − | {{tp|p=33045402|t=2020. The vitamin D for COVID-19 (VIVID) trial: A pragmatic cluster-randomized design.|pdf=|usr=020}}
| |
| − | {{tp|p=33043163|t=2020. Remdesivir for coronavirus 2019 (COVID-19): More promising but still unproven.|pdf=|usr=020}}
| |
| − | {{tp|p=33036833|t=2020. Theoretical novel COVID-19 vaccination risk of rare and severe adverse events versus COVID-19 mortality.|pdf=|usr=020}}
| |
| − | {{tp|p=33096485|t=2020. Blockade of an innate immune amplifier to fight immune hyperactivation in COVID-19?|pdf=|usr=020}}
| |
| − | {{tp|p=33038768|t=2020. Tocilizumab is recommended for the treatment of severe COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33048175|t=2020. Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33188451|t=2020. Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33090434|t=2020. Could dantrolene be explored as a repurposed drug to treat COVID-19 patients by restoring intracellular calcium homeostasis?|pdf=|usr=020}}
| |
| − | {{tp|p=33090432|t=2020. A critical appraisal of evidence in the use of preprocedural mouthwash to avoid SARS-CoV-2 transmission during oral interventions.|pdf=|usr=020}}
| |
| − | {{tp|p=33195565|t=2020. Phytogenic Products and Phytochemicals as a Candidate Strategy to Improve Tolerance to Coronavirus.|pdf=|usr=020}}
| |
| − | {{tp|p=33083627|t=2020. Computer-aided drug design against spike glycoprotein of SARS-CoV-2 to aid COVID-19 treatment.|pdf=|usr=020}}
| |
| − | {{tp|p=33033884|t=2020. Umbilical cord: an allogenic tissue for potential treatment of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33046268|t=2020. Puzzling out the COVID-19: Therapy targeting HLA-G and HLA-E.|pdf=|usr=020}}
| |
| − | {{tp|p=33166584|t=2020. Optimization and evaluation of propolis liposomes as a promising therapeutic approach for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33100674|t=2020. Therapeutic status of hydroxychloroquine in COVID-19: A review.|pdf=|usr=020}}
| |
| − | {{tp|p=33134212|t=2020. A New Look at the LDRT treatment for COVID-19 Associated Pneumonia: The Issues of Antiviral Resistance and Virus Spread-Ability.|pdf=|usr=020}}
| |
| − | {{tp|p=33122473|t=2020. Identification of therapeutic drugs against COVID-19 through computational investigation on drug repurposing and structural modification.|pdf=|usr=020}}
| |
| − | {{tp|p=33111624|t=2020. Deciphering underlying mechanism of Sars-CoV-2 infection in humans and revealing the therapeutic potential of bioactive constituents from Nigella sativa to combat COVID19: in-silico study.|pdf=|usr=020}}
| |
| − | {{tp|p=33111622|t=2020. In silico analysis of the interactions of certain flavonoids with the receptor-binding domain of 2019 novel coronavirus and cellular proteases and their pharmacokinetic properties.|pdf=|usr=020}}
| |
| − | {{tp|p=33111618|t=2020. Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-alpha with in-vitro effective drug ivermectin.|pdf=|usr=020}}
| |
| − | {{tp|p=33107812|t=2020. Secondary metabolites from spice and herbs as potential multitarget inhibitors of SARS-CoV-2 proteins.|pdf=|usr=020}}
| |
| − | {{tp|p=33103616|t=2020. Natural phyto, compounds as possible noncovalent inhibitors against SARS-CoV2 protease: computational approach.|pdf=|usr=020}}
| |
| − | {{tp|p=33103586|t=2020. High-throughput virtual screening of drug databanks for potential inhibitors of SARS-CoV-2 spike glycoprotein.|pdf=|usr=020}}
| |
| − | {{tp|p=33179586|t=2020. Reprofiling of approved drugs against SARS-CoV-2 main protease: an in-silico study.|pdf=|usr=020}}
| |
| − | {{tp|p=33179568|t=2020. In-silico drug repurposing for targeting SARS-CoV-2 main protease (M(pro)).|pdf=|usr=020}}
| |
| − | {{tp|p=33172342|t=2020. Nanobodies: an unexplored opportunity to combat COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33140086|t=2020. Longitudinal analysis of serology and neutralizing antibody levels in COVID19 convalescents.|pdf=|usr=020}}
| |
| − | {{tp|p=33073845|t=2020. BCG as an adjunct or alternative vaccine to prevent COVID-19?|pdf=|usr=020}}
| |
| − | {{tp|p=33031764|t=2020. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.|pdf=|usr=020}}
| |
| − | {{tp|p=33031761|t=2020. Antiviral monotherapy for hospitalised patients with COVID-19 is not enough.|pdf=|usr=020}}
| |
| − | {{tp|p=33091364|t=2020. Use of adenovirus type-5 vectored vaccines: a cautionary tale.|pdf=|usr=020}}
| |
| − | {{tp|p=33010835|t=2020. Remdesivir and COVID-19 - Authors' reply.|pdf=|usr=020}}
| |
| − | {{tp|p=33010833|t=2020. Remdesivir and COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33010832|t=2020. Remdesivir and COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33010831|t=2020. Remdesivir and COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33010830|t=2020. Remdesivir and COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33010825|t=2020. Leveraging the advances in HIV for COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33078096|t=2020. Molecular Docking and ADMET Study of Bioactive Compounds of Glycyrrhiza glabra Against Main Protease of SARS-CoV2.|pdf=|usr=020}}
| |
| − | {{tp|p=33037683|t=2020. The COVID-19 era and pediatric procedural sedation: A consecutive case series with an emphasis on preparation, precautions, and risk reduction.|pdf=|usr=020}}
| |
| − | {{tp|p=33163186|t=2020. Polymyxin B haemoperfusion treatment for respiratory failure and hyperferritinaemia due to COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33051923|t=2020. Attenuating COVID-19 infection and inflammation: Lessons from asthma.|pdf=|usr=020}}
| |
| − | {{tp|p=33069616|t=2020. Calcineurin Inhibitors and COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33138947|t=2020. Covid-19 and vit-d: Disease mortality negatively correlates with sunlight exposure.|pdf=|usr=020}}
| |
| − | {{tp|p=33120121|t=2020. DFT calculations towards the geometry optimization, electronic structure, infrared spectroscopy and UV-vis analyses of Favipiravir adsorption on the first-row transition metals doped fullerenes; a new strategy for COVID-19 therapy.|pdf=|usr=020}}
| |
| − | {{tp|p=33110915|t=2020. Mesenchymal stem cell treatment in a critically ill COVID-19 patient: a case report.|pdf=|usr=020}}
| |
| − | {{tp|p=33059757|t=2020. Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients.|pdf=|usr=020}}
| |
| − | {{tp|p=33089452|t=2020. Human Hematopoietic Stem, Progenitor, and Immune Cells Respond Ex Vivo to SARS-CoV-2 Spike Protein.|pdf=|usr=020}}
| |
| − | {{tp|p=33161559|t=2020. Nanoconjugates-Based Stem Cell Therapy for the Management of COVID-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33188579|t=2020. Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection.|pdf=|usr=020}}
| |
| − | {{tp|p=33106741|t=2020. Discovery of small molecule PLpro inhibitor against COVID-19 using structure-based virtual screening, molecular dynamics simulation, and molecular mechanics/Generalized Born surface area (MM/GBSA) calculation.|pdf=|usr=020}}
| |
| − | {{tp|p=33152262|t=2020. Malleability of the SARS-CoV-2 3CL M(pro) Active-Site Cavity Facilitates Binding of Clinical Antivirals.|pdf=|usr=020}}
| |
| − | {{tp|p=33099554|t=2020. SARS-CoV-2 in Semen.|pdf=|usr=020}}
| |
| − | {{tp|p=33070138|t=2020. Semen Does Not Cause Additional Risk for SARS-CoV-2 Transmission during Sexual Contact.|pdf=|usr=020}}
| |
| − | {{tp|p=33039209|t=2020. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.|pdf=|usr=020}}
| |
| − | {{tp|p=33139139|t=2020. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge.|pdf=|usr=020}}
| |
| − | {{tp|p=33097312|t=2020. Exploring uncertainty and risk in the accelerated response to a COVID-19 vaccine: Perspective from the pharmaceutical industry.|pdf=|usr=020}}
| |
| − | {{tp|p=33082015|t=2020. Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.|pdf=|usr=020}}
| |
| − | {{tp|p=33071000|t=2020. Bacillus Calmette-Guerin (BCG) vaccine generates immunoregulatory cells in the cervical lymph nodes in guinea pigs injected intra dermally.|pdf=|usr=020}}
| |
| − | {{tp|p=33069443|t=2020. COVID-19 vaccine trials: Duty of care and standard of prevention considerations.|pdf=|usr=020}}
| |
| − | {{tp|p=33081331|t=2020. The Strange Case of BCG and COVID-19: The Verdict Is Still up in the Air.|pdf=|usr=020}}
| |
| − | {{tp|p=33153096|t=2020. COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response.|pdf=|usr=020}}
| |
| − | {{tp|p=33127010|t=2020. Cost-Effectiveness of Antiviral Treatments for Pandemics and Outbreaks of Respiratory Illnesses, Including COVID-19: A Systematic Review of Published Economic Evaluations.|pdf=|usr=020}}
| |
| − | {{tp|p=33127008|t=2020. The Role of Health Economics and Outcomes Research in Addressing Coronavirus Disease 2019 (COVID-19).|pdf=|usr=020}}
| |
| − | {{tp|p=33100613|t=2020. Molecular docking analysis of selected phytochemicals against SARS-CoV-2 M(pro) receptor.|pdf=|usr=020}}
| |
| − | {{tp|p=33097047|t=2020. Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series.|pdf=|usr=020}}
| |
| − | {{tp|p=33154979|t=2020. Baseline results of a living systematic review for COVID-19 clinical trial registrations.|pdf=|usr=020}}
| |
| − | {{tp|p=33117894|t=2020. Baseline results of a living systematic review for COVID-19 funded research projects.|pdf=|usr=020}}
| |
| − | {{tp|p=33164550|t=2020. Individuating Possibly Repurposable Drugs and Drug Targets for COVID-19 Treatment Through Hypothesis-Driven Systems Medicine Using CoVex.|pdf=|usr=020}}
| |
| − | {{tp|p=33037029|t=2020. Covid-19: Experts advise cautious optimism for neutralising antibodies after early results.|pdf=|usr=020}}
| |
| − | {{tp|p=33032983|t=2020. Covid-19: FDA defies Trump to publish rigorous vaccine development guidelines.|pdf=|usr=020}}
| |
| − | {{tp|p=33023934|t=2020. Covid-19 elimination: consider population level effects of vaccine.|pdf=|usr=020}}
| |
| − | {{tp|p=33086342|t=2020. Understanding COVID-19 Vaccines and Their Development.|pdf=|usr=020}}
| |
| − | {{tp|p=33080582|t=2020. Nitric oxide's physiologic effects and potential as a therapeutic agent against Covid-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33055254|t=2020. The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells.|pdf=|usr=020}}
| |
| − | {{tp|p=33173010|t=2020. Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives.|pdf=|usr=020}}
| |
| − | {{tp|p=32579163|t=2020. Missed Opportunities on Emergency Remdesivir Use.|pdf=|usr=020}}
| |
| − | {{tp|p=33160452|t=2020. Emergency use authorisation for COVID-19 vaccines: lessons from Ebola.|pdf=|usr=020}}
| |
| − | {{tp|p=33159850|t=2020. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination.|pdf=|usr=020}}
| |
| − | {{tp|p=33125926|t=2020. Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essential.|pdf=|usr=020}}
| |
| − | {{tp|p=33113304|t=2020. Audio Interview: A New Monoclonal Antibody for Covid-19.|pdf=|usr=020}}
| |
| − | {{tp|p=33093684|t=2020. SARS-CoV-2 M(pro) inhibitors and activity-based probes for patient-sample imaging.|pdf=|usr=020}}
| |
| − | {{tp|p=33082574|t=2020. Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33140777|t=2020. Structure-based lead optimization of herbal medicine rutin for inhibiting SARS-CoV-2's main protease.|pdf=|usr=020}}
| |
| − | {{tp|p=33167083|t=2020. Immunoprotective potential of Ayurvedic herb Kalmegh (Andrographis paniculata) against respiratory viral infections - LC-MS/MS and network pharmacology analysis.|pdf=|usr=020}}
| |
| − | {{tp|p=33002827|t=2020. Rhamnocitrin extracted from Nervilia fordii inhibited vascular endothelial activation via miR-185/STIM-1/SOCE/NFATc3.|pdf=|usr=020}}
| |
| − | {{tp|p=32902005|t=2020. Glycyrrhizin: An old weapon against a novel coronavirus.|pdf=|usr=020}}
| |
| − | {{tp|p=32996197|t=2020. Arenaria kansuensis attenuates pulmonary fibrosis in mice via the activation of Nrf2 pathway and the inhibition of NF-kB/TGF-beta1/Smad2/3 pathway.|pdf=|usr=020}}
| |
| − | {{tp|p=33051297|t=2020. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.|pdf=|usr=020}}
| |
| − | {{tp|p=33172366|t=2020. The PentaFOLD 3.0 algorithm for the selection of stable elements of secondary structure to be included in vaccine peptides.|pdf=|usr=020}}
| |
| − | {{tp|p=33115218|t=2020. The influence of vaccination against tuberculosis with the Bacillus-Calmette-Guerin(BCG) vaccine on COVID-19 incidence and mortality - review of the literature.|pdf=|usr=020}}
| |
| − | {{tp|p=33033203|t=2020. Inhibiting Ebola virus and SARS-CoV-2 entry.|pdf=|usr=020}}
| |
| − | {{tp|p=33033196|t=2020. A call to test new vaccines head to head, in monkeys.|pdf=|usr=020}}
| |
| − | {{tp|p=33154108|t=2020. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33154107|t=2020. De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2.|pdf=|usr=020}}
| |
| − | {{tp|p=33154106|t=2020. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike.|pdf=|usr=020}}
| |
| − | {{tp|p=33087460|t=2020. Understanding COVID-19 vaccine efficacy.|pdf=|usr=020}}
| |
| − | {{tp|p=33164326|t=2020. Advancements in protein nanoparticle vaccine platforms to combat infectious disease.|pdf=|usr=020}}
| |
